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Background: Glutamine is considered conditionally essential during critical illness and supplementation of 
the nutrient has become commonplace among adult ICU populations. However, recent concern over the 
safety of this practice has highlighted the need for focused research on plasma glutamine levels in specific 
patient groups. There is limited evidence for glutamine supplementation in children, with even les s data 
available on plasma concentrations within this group. The aim of this study was to describe plasma 
glutamine concentration among critically ill children on admission to and on day two of Paediatric Intensive 
Care Unit (PICU) stay, and to identify associations between plasma glutamine and markers of clinical 
condition, nutritional status and intake, and clinical outcome.   
Methods: This descriptive cross-sectional study investigated the plasma glutamine concentrations of 
patients admitted to a tertiary PICU in the Western Cape, South Africa, over a period of one month. Plasma 
glutamine was analysed using blood samples collected on admission, and on day two of PICU stay. Markers 
of clinical condition on admission (diagnostic profile, severity of disease, presence of infectious disease, and 
routine biochemistry) were collected. Age-appropriate anthropometry was conducted, and the nutritional 
status of participants was assessed using World Health Organization Z scores. Nutritional intake was 
recorded and analysed for the first two days of PICU stay.   
Results: Seventy six participants were included in this study, many of whom (47%) were post-operative 
cardiac patients. Plasma glutamine concentrations were normal for most participants on admission 
(median 556.5 umol/l, IQR 459- 664.5 umol/l) and on day two of PICU stay (median 529.0 umol/l, IQR 
356.0-716.0 umol/l). No obvious change in plasma levels occurred during this period. Significant differences 
in plasma glutamine were found between medical and elective surgery (p = 0.007) and trauma (p = 0.013) 
patients with trauma observed to have the lowest concentrations on admission (mean 450.3 ± 166.7 
umol/l).  Differences were also observed between cardiology and gastroenterology (p = 0.018), and 
between sepsis and pulmonology (p = 0.031), burns (p = 0.035), gastroenterology (p = 0.006), and ‘other’ (p 
= 0.049) diagnoses. Participants with sepsis had the highest plasma glutamine on admission (mean 736.3 ± 
142.5 umol/l). Participants with higher plasma glutamine on admission tended to have longer hospital stays 
(p = 0.067), and a higher mortality risk (p = 0.052). Although no link was made with mortality, those who 
died had higher plasma glutamine on day two of PICU stay (p = 0.057).  
Conclusion:  This study found normal plasma glutamine concentrations among critically ill children over the 
first two days of PICU stay. Significant differences were found in plasma glutamine between diagnostic 
groups, with sepsis and trauma identified as areas for future study. A tendency was demonstrated toward 
poorer outcome and increased mortality risk among those with high plasma glutamine. Additional 
exploratory research is required to better understand plasma glutamine in different paediatric subgroups.   
 
  




Agtergrond: Glutamien word beskou as kondisioneel noodsaaklik tydens kritiese siektes en aanvullings van 
die nutriënt word gereeld in intensiewe sorg eenhede gebruik. Onlangse kommer oor die veiligheid van dié 
praktyk beklemtoon die behoedfte vir meer gefokusde navorsing oor plasma glutamienvlakke in spesifieke 
pasiënt populasies. Daar is ‘n gebrek aan navorsing oor die rol van glutamien aanvullings in kinders, en data 
oor plasma  konsentrasies in die groep is selfs meer beperk. Die doel van die studie was om  plasma 
glutamien konsentrasies in kinders in die pediatriese intensiewe sorg eenheid (PICU) te beskryf, beide met 
hospitaal toelating en op dag twee van verblyf; en om assosiasies tussen plasma glutamien en merkers van 
kliniese toestand, voedingstatus, inname en ook kliniese uitkomste te identifiseer.  
Metodes: Hierdie dwarssnit beskrywende studie het die plasma glutamien konsentrasies ondersoek in  
pasiënte opgeneem tot ‘n tersiêre PICU in die Wes-Kaap, Suid Afrika, oor ‘n tydperk van een maand. 
Bloedmonsters is geneem met toelating en op die tweede dag van PICU verblyf en is geanaliseer vir plasma 
glutamine konsentrasie. Merkers van kliniese toestande met toelating (diagnostiese profiel, erns van siekte, 
teenwoordigheid van infeksie, en roetine biochemie) is ingesamel. Ouderdoms-toepaslike antropometrie is 
geneem en voedingstatus is bepaal met die Wêreldgesondheidsorganisasie Z-tellings. Voedingsinname is 
gedokumenteer en geanaliseer vir die eerste twee dae van PICU verblyf.  
Resultate: Die studie het ses-en-sewentig deelnemers ingesluit, die meerderheid (47%) was post-kardiale 
chirurgie pasiënte. Plasma glutamien konsentrasies was normaal vir meeste van die deelnemers met 
toelating [mediaan 556.5 umol/l, interkwartielvariasiewydte (IQR) 459- 664.5 umol/l] en op dag twee PICU 
verblyf (mediaan 529.0 umol/l, IQR 356.0-716.0 umol/l). Geen ooglopende veranderinge in plasma vlakke 
het tydens die periode plaasgevind nie. Beduidende verskille in plasma glutamien is gevind tussen mediese 
en elektiewe chirurgie (p = 0.007) en ook trauma (p = 0.013) pasiënte, met die laagste konsentrasies met 
toelating in trauma pasiënte (gemiddeld 450.3 ± 166.7 umol/l). Verskille in glutamien konsentrasie is ook 
waargeneem tussen kardiologie en gastroënterologie (p = 0.018), tussen sepsis en pulmonologie (p = 
0.031), brandwonde (p = 0.035), gastroënterologie (p = 0.006), en ‘ander’ (p = 0.049) diagnoses. 
Deelnemers met sepsis het die hoogste glutamien met toelating gehad (gemiddeld 736.3 ± 142.5 umol/l). 
Deelnemers met hoër plasma glutamien met toelating was meer geneig om langer in die hospitaal te bly (p 
= 0.067), en het ‘n hoër sterfterisiko gehad (p = 0.052). Alhoewel daar geen verband met mortaliteit was 
nie, het dié wat oorlede is hoër plasma glutamien vlakke getoon op dag twee van PICU verblyf (p = 0.057). 
Gevolgtrekking: Die studie het normale plasma glutamien konsentrasies in kritiese siek kinders tydens die 
eerste twee dae van PICU verblyf gevind. Beduidende verskille is gevind in plasma glutamien tussen 
diagnostiese groepe, met sepsis en trauma geïdentifiseer as fokus areas vir toekomstige navorsing.  ‘n 
Neiging na swakker uitkomste en hoër sterfterisiko in diegene met hoër plasma glutamien is 
gedemonstreer. Addisionele verkennende navorsing word benodig vir ‘n beter begrip van  plasma glutamien 
in verskillende pediatriese subgroepe. 
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The amino acid glutamine was discovered over a century ago, having first been isolated in 1883 by Schultze 
and Boshard from beet juice.1 Later, in 1932, it was identified in abundance in gliadin, a protein found in 
wheat.2 It was not until 1935, however, that the enzymatic synthesis of glutamine from glutamate and 
ammonia was discovered by Krebs using rat and guinea pig kidney tissue.3 This provided the first evidence 
that glutamine is likely present in most mammalian tissues. This was a profound discovery- considering the 
scientific limitations of the time and the innate instability of glutamine in vitro.2  
 
Since these early discoveries, research on the amino acid (particularly in rat models) gained traction and 
generated important functional knowledge on the nutrient. One of the earliest discoveries of glutamine 
function was its role in maintaining pH balance, which was described by Goodman and colleagues.4 Shortly 
thereafter, Pozefsky identified elevated glutamine release from muscle tissue when compared to other 
amino acids.5 In their ground-breaking work, Windmeuller and Speath established the uptake of glutamine 
from the intestine, so opening the door to further research into its role in gut health.6,7 Knowledge on the 
amino acid has since grown exponentially. Glutamine is now appreciated as being unique in comparison to 
other amino acids in terms of its diverse functional capacity and contribution to various biological systems 
and homeostasis.2   
 
Glutamine has been in the spotlight for several decades for its therapeutic potential during critical illness.  
However, the focus on this amino acid has changed direction several times. Promising results from early 
intervention studies in the 1980s established a place for glutamine supple mentation of the critically ill, 
seemingly with no risk of harm.8,9 Much research followed, investigating the effects of glutamine 
supplementation among various patient groups.10 Consequently, support grew for routine supplementation 
during critical illness.11,12  
 
There has, however, been a recent shift in opinion. In 2013, a large multicentre trial reported harm 
following high dose supplementation of glutamine to critically ill adults .13 This divided the research 
community into those who believed supplementation should cease altogether,14 and others advocating a 
more targeted approach.15–17 What became resoundingly clear following this controversy, was the need for 
a deeper understanding of the patient populations who may benefit from glutamine supplementation and 
those who would not.18 As such, a ‘back to basics’ approach seemed appropriate, in which observational 
research into plasma glutamine concentrations of specific patient subgroups took precedent over 
intervention trials.19  
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The current study, which focuses on plasma glutamine concentration among critically ill children, is a 
reflection of the current move toward observation and understanding within glutamine research. In 
paediatric populations, intervention studies have yielded no defini tive answers regarding glutamine 
supplementation thus far, with few studies having measured plasma glutamine prior to supplementation.20 
Limited observational research has been done on plasma glutamine concentrations among critically ill 
children – warranting further study within this subgroup.21,22   
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2. Literature Review  
Glutamine in the human body 
Glutamine is the most abundant amino acid in the plasma and muscle tissue of humans. Skeletal muscle is 
the major site of production and storage of glutamine, accounting for up to 90 % of the body’s pool .23   
Glutamine in the plasma 
Normal plasma glutamine in adult populations has been established at concentrations of 420-930 umol/l.24 
Plasma glutamine is derived from several sources, the first being skeletal muscle degradation. During 
periods of stress, increased demand for glutamine triggers net proteolysis of skeletal muscle .25 The 
resulting free glutamine is exported from the muscle cell’s cytosol into the plasma in an attempt to 
maintain physiological concentrations.26  
 
De novo synthesis of glutamine by the enzyme glutamine synthase is the second so urce of plasma 
glutamine. Although this occurs mainly in skeletal muscle, synthesis has also been shown to occur under 
certain conditions in organs such as the lungs,27 brain, liver, and in adipose tissue.28,29 During periods of 
stress, human lungs demonstrate the ability to release glutamine as a result of glucocorticoid signalling and 
glutamine synthase expression. Although a minor contributor to the glutamine pool, adipose tissue has 
recently been thought to be a potentially important source of the amino acid.29 Despite the liver’s ability to 
synthesise and catabolise glutamine, it is thought to play an insignificant role in the body’s overall 
glutamine pool. Glutamine flux in the liver is thought to occur as part of regulatory effects during acidosis 
and hyperammonemia.30  
 
The free glutamine pool is the third source of plasma glutamine. During the diseased state , the free 
glutamine pool is decreased as it donates glutamine to the plasma.31  
 
Dietary intake of glutamine in the form of protein is another source of exogenous glutamine which enters 
the plasma. Together, glutamate and glutamine comprise 5 – 9% of dietary protein.32 
Glutamine in the tissues 
Tissue concentrations of glutamine are higher than in the plasma. The steep uphill gradient of glutamine 
concentration between the plasma and tissues is maintained by active transport – primarily through the 
sodium potassium (Na+/K+) pump. This transport system requires hydrolysis of Adenosine Triphosphate 
(ATP) by the enzyme Na+/K+ ATPase.26 Intracellular concentrations of glutamine are also influenced by the 
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cellular production and uptake of glutamine from de novo synthesis, as well as from protein breakdown.2 
Concentrations of glutamine in various tissues vary considerably, with enterocyte concentrations at 2-4 
mmol/l compared to skeletal muscle and liver concentrations of 5-20 mmol/l. It is therefore suspected that 
plasma concentration is not the only factor influencing cellular content, and that additional factors play 
varying roles in determining glutamine concentration in the different tissues.26 
Functions of glutamine 
Like other amino acids, glutamine provides substrate for protein metabolism. It is, however, considered 
unique in that it plays a central role in numerous biological and homeostatic pathways – including energy 
metabolism, immune function, tissue protection, antioxidant capacity, pH regulation, and in the protection 
of the intestinal barrier, as summarised in Figure 1 (below).20,33  
 
Figure 1: Functions of glutamine (adapted from Mok and Hankard, 2011)20 
 
Glutamine is referred to as the universal precursor, in that it is involved in the synthesis not only of 
peptides and proteins, but also of the neurotransmitter glutamate, hexosamine, purine and pyrimidine, and 
therefore nucleic acid and nucleotides,23,26 and the amino acid Arginine.34 
Protein metabolism 
Glutamine is considered an important regulator of protein turnover. In addition to providing a nitrogen 
source for protein synthesis, glutamine serves as a major transporter of nitrogen between tissues – from 
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skeletal muscle in particular to the intestine, kidney, neurons, immune cells, and liver.35 Unlike other amino 
acids, glutamine is considered a non-toxic carrier of nitrogen.2 During periods of stress when glutamine is 
utilised for purposes other than protein synthesis, a significant amount of ammonia is released during its 
degradation. This ammonia is, however, immediately scavenged by organs before being able to enter the 
circulation and cause toxicity.26 
 
Glutamine, along with other amino acids, is also thought to inhibit protein degradation in organs such as 
skeletal muscle, liver, and the intestine by directly influencing the autophagic pathway of proteolysis .20 
Suggested mechanisms for this, as seen in rat models, include intracellular signalling by amino ac id 
receptors, activation of the mTOR (mammalian target of rapamycin) pathway, 36,37 which suppresses 
autophagic proteolysis through the attenuation of MAPK (Mitogen-Activated Protein Kinases) 
phosphorylation, and the increase in Heat Shock Protein 70 (HSP70) .20 The inhibitory effect that glutamine 
has on proteolysis may also be related to its effect on cellular hydration, as protein synthesis is influenced 
by the degree to which cells shrink or swell. By regulating osmotic swelling in cells, anabolic signals are sent 
– as opposed to catabolic signals that occur during cell shrinkage.2,38 In short, glutamine has a protein-
sparing effect.  
Glucose metabolism  
The carbon skeleton of glutamine is an important substrate for gluconeogenesis in the liver, intestine, and 
kidney. During gluconeogenesis, non-carbohydrate derived carbon substrates are used to produce glucose. 
This is a major regulator of blood glucose concentration.2  
 
During critical illness when hyperglycaemia and insulin resistance are common, glutamine is also thought to 
influence glucose metabolism by upregulating insulin sensitivity,39 and by acting as a signalling molecule for 
insulin secretion.25,40  
Energy production 
Figure 2 (below) illustrates the major pathways of energy production that glutamine is involved in.41 Once 
in the mitochondria, glutamine is catabolised by the enzyme glutaminase into glutamate – a reaction that 
also releases ammonia.29 Glutamate (and by association glutamine) plays an important role in the 
Tricarboxcylic Acid (TCA) cycle by serving as the major source of the intermediate ἀ -ketoglutarate. The TCA 
or Krebs cycle plays a central role in cellular metabolism, by contributing to energy production.41 Glutamate 
is converted into ἀ-ketoglutarate through transamination or through deamination by glutamate 
dehydrogenase. Where glucose supply is sufficient, transamination usually occurs. However, during 
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physiological conditions in which glucose is limited, the deamination pathway becomes the major route for 


















Figure 2: Role of glutamine in energy production41  
ATP: Adenosine Triphosphate; AST: Alanine Amino Transferase;  AST: Aspartate Aminotransferase; Cit: 
Citrate; Cys: Cysteine; Fum: Fumarate; GLS: Glutaminase; gln: Glutamine; Glu: Glutamate; GDH: Glutamate 
Dehydrogenase; Icit: Isocitrate; IDH1: Isocitrate Dehydrogenase; KG: Ketoglutarate; Lac: Lactate; Mal: 
Malate; ME: Malic Enzyme; NADPH: Nicotinamide Adenine Dinucleotide Phosphate; OAA: Oxaloacetate; 
Pyr: Pyruvate; SCoA: Coenzyme A; Succ: Succinate; SS: SuccinylCoA Synthetase.  
 
Glutamine-derived ἀ-ketoglutarate serves multiple purposes – first as a major source of energy in the TCA 
cycle (Figure 2 above). This is primarily achieved by the production of ATP via Succinyl CoA synthetase. In 
rapidly dividing cells, ATP can also be produced by the export of malate into the cytosol. In a series of 
reactions, malate is converted into pyruvate and then into lactate with the resulting release of ATP by 
glycolysis. The entry of glutamine-derived glutamate into the TCA cycle also plays a role in the production 
of NADPH (Nicotinamide Adenine Dinucleotide Phosphate) from malate, as seen in Figure 2. 41 NADPH 
increases antioxidant capacity by reducing glutathione from its oxidised state (discussed below), and is 
necessary for cell proliferation.35 Thirdly, ἀ-ketoglutarate from glutamine takes part in anaplerotic reactions 
that replenish TCA cycle intermediates – particularly in rapidly dividing cells. In such tissues, intermediates 
exit the TCA cycle at various stages. In combination with amino acids released from peripheral tissues into 
the circulation, these intermediates produce ATP, nucleotides, phospholipids, and sterols – thereby 
supporting rapid proliferation of cells and contributing towards metabolic homeostasis .26  
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Gut health and the intestinal barrier 
One of the most well-documented functions of glutamine is its role as a major oxidative fuel and nucleotide 
substrate for rapidly proliferating cells, particularly those of the gastrointestinal tract and  immune 
system.42 Enterocytes in the gastrointestinal tract, the small bowel in particular, are the major consumers 
of glutamine, utilising an estimated 30% of the body’s total pool .43 Most enteral glutamine is metabolised 
within the intestine itself, with only 25% being transported to other organs.43,44  
 
Glutamine is thought to influence enterocyte proliferation through the activation of  MAPK45 and by 
enhancing the effect of several growth factors.46 By providing a fuel source for intestinal and gut- 
associated lymphoid tissue (GALT), glutamine is thought to contribute to the integrity of the intestinal 
barrier.42  
 
Glutamine is also a precursor for hexosamines, which are important in the prevention of bacterial 
translocation by means of surface mucin and tight intracellular junctions.42 Tight junctions are comprised of 
various proteins that act as a barrier, regulating nutrient uptake and preventing harmful pathogens from 
entering the lumen of the gut.43 Glutamine is thought to influence the expression of these proteins – thus 
further maintaining the intestinal barrier.47,48   
 
Through its role in antioxidant defence and tissue protection (discussed below), glutamine also offers 
intestinal cells protection from stress by inhibiting the pro-inflammatory response, reducing apoptosis and 
by enhancing autophagy.43 
Antioxidant capacity  
Glutamine influences antioxidant defence by serving as a precursor to glutamate, which in turn is used to 
synthesise the major antioxidant glutathione.20 Glutathione is present in both reduced and oxidised forms, 
the ratio of which determines the redox capacity of the cell. In addition to antioxidant functioning, 
glutathione also regulates immune function, the production of cytokines, cell division and apoptosis, 
genetic expression, and Deoxyribonucleic Acid (DNA) synthesis.49  
 
In vivo experiments have demonstrated a protective effect of the reduced form of glutathione against 
oxidative stress in the heart,50 lung, and gut tissues of rats.51 In humans, glutathione depletion in the 
skeletal muscle of surgical patients has been prevented by glutamine supplementation. In addition, liver 
damage during neonatal sepsis has shown to be attenuated by the synthesis of glutathione .20 These, along 
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with other short-term studies, have demonstrated the potential role of glutamine in ameliorating oxidative 
stress - making this an important avenue for future study.2 
Immune function 
Glutamine is an important substrate for macrophages and lymphocytes. By providing fuel for these cells, 
glutamine influences immune function.33 Glutamine is also required for purine and pyrimidine synthesis, 
providing important building blocks once immune cells are activated.25 In addition, glutamine is also 
required for the expression of certain cell surface markers, which are also necessary for the activation of 
the immune response.52 
 
The amino acid has also been shown to modulate cytokine production, thereby proffering anti- 
inflammatory effects. The mechanism for this is thought to be due to reduced activation of Nuclear Factor-
kB.
53 This transcription factor is involved in both innate and adaptive immunity and the inflammatory 
response through expression of genes that encode cytokines.54  
Tissue protection 
The anti-inflammatory effects of glutamine may also be the result of elevated expression of Heat Shock 
Proteins (HSPs). HSPs or stress proteins are produced by cells in response to physiological stress .25 Certain 
HSPs act as molecular chaperones that work to refold or repair damaged proteins or to denature proteins 
that are irreparably damaged – thereby maintaining cell function.20 HSPs have been classified into groups: 
HSP27, HSP40, HSP60, HSP70, HSP90, and HSP110. Glutamine is thought to enhance the expression of 
HSP25, HSP70, and HSP72.21 Of these, HSP70 has been most studied and is thought to influence the role 
that glutamine plays in tissue protection and in the mitigation of pro-inflammatory cytokine release. HSP70 
is also thought to supress apoptosis.53 During states of glutamine depletion, such as during critical illness, 
the expression of HSP70 is impaired. Glutamine-depleted cells with reduced HSP70 and antioxidant activity 
have been shown to be more susceptible to apoptosis.20 Conversely, up-regulation of HSP70 in rat models21 
and adult burn victims has also been linked to reduced mortality. 55 Thus, interest in the role of HSP70 
during critical illness has grown.  
 
In animal models, glutamine has been shown to further diminish the inflammatory response by controlling 
the activity of nitric oxide synthase in organs such as the heart and lungs.53 One hypothesis for this 
mechanism is in glutamine’s capacity as precursor to Arginine , which is able to enhance nitric acid 
production.20,34 However, in human models, the increase in nitric oxide following glutamine administration 
during pro-inflammatory states has not been consistently demonstrated.56  




Because glutamine is a non-toxic transporter of ammonia, it plays a fundamental role in maintaining pH 
homeostasis through its metabolism in the kidney.20,33 During periods of acidosis (either metabolic or 
respiratory), glutamine uptake by the kidney increases. Enzymatic cleaving of glutamine by glutami nases 
releases ammonia from the amide and amino nitrogens.2 Ammonia enters the renal tubule lumen where it 
combines with free hydrogen (H+) ions to form ammonium, which is then excreted in the urine. The acid-
base balance is therefore maintained.33    
Glutamine in adult critical illness 
Glutamine plays an essential role in producing the substrates necessary for cellular homeostasis and 
survival.26 As such, it has been widely identified as a key nutrient in the physiological response to injury.57 
The amino acid is thought to attenuate inflammation, offer protection from tissue injury, and preserve 
metabolic function during periods of stress.25 A shortage of glutamine would imply that the host response 
to critical illness may be compromised.26  
Glutamine: conditionally essential during critical illness 
In light of the body’s ability to produce glutamine, it has traditionally been regarded as a no n-essential 
amino acid. During critical illness however, it is considered conditionally essential - as endogenous 
consumption by the gut, immune cells, kidney, and liver may exceed its rate of synthesis.25  
Glutamine in the plasma and muscle during critical illness  
 Prevalence of glutamine depletion 
Both plasma and tissue glutamine concentrations have been shown to decrease during critical illness.26 In 
mixed intensive care unit (ICU) populations, plasma glutamine depletion has been observed on admission, 
with a prevalence of 31%,24 38%,58 44%,59 and as high as 65%60 reported among individual study cohorts. 
More specifically, reduced plasma glutamine among surgical patients has been reported by several authors. 
A study on well-nourished patients undergoing colorectal surgery demonstrated a reduction of plasma 
glutamine from 625 ± 22 umol/l prior to surgery to 431 ± 17 umol/l post-operatively, and of muscle 
glutamine from 13.2 ± 1.4 mmol/l to 9.6 ± 2.0 mmol/l.61 Glutamine concentration in muscle tissue has also 
been shown to reduce significantly within the first 24 hours after elective abdominal surgery .62 More 
recently, Viggiano and colleagues confirmed previous findings by showing post-operative reductions in 
plasma glutamine concentration - more so after major surgery.63,64 
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Recent data suggest that plasma glutamine depletion is more commonplace among non-elective medical 
admissions.58,60 Patients with severe pancreatitis showed a drop in plasma glutamine to less than half that 
of control subjects, and a reduction in muscle glutamine to less than 20% when compared to controls.65 
Low plasma glutamine has also been demonstrated among patients with trauma,66 burns,67 and 
malnutrition,68 and has been shown to remain low for several days following major surgery64 and burns.67 
Reduced glutamine concentration in skeletal muscle69 and plasma24,58 have also been reported among 
septic patients.  
 Elevations in plasma glutamine 
Although to a far lesser degree, elevated plasma glutamine concentrations have been demonstrated among 
certain critically ill patients. The prevalence of this is not consistently reported on, however, one study 
found that 7% of patients had raised plasma glutamine levels, defined as >930 umol/l.58 Elevated plasma 
glutamine with associated increases in ammonia and hepatic encephalopathy have been well documented 
among patients with acute fulminant liver failure, but are less well described among those with chronic or 
acute-on-chronic liver disease.70 More recently, Helling and colleagues studied a cohort of 100 patients 
with liver failure. The group demonstrated that all subgroups of liver failure, including chronic, acute-on-
chronic, acute fulminant, and post-hepatectomy, may be associated with raised plasma glutamine levels.71 
 
Patients with chronic renal failure have also been shown to have elevated plasma glutamine levels, as 
uptake of glutamine by the kidneys is markedly reduced.72,73 In this instance, raised plasma glutamine has 
been shown to positively correlate with blood levels of the waste products urea and ammonia. Such 
alterations in amino acid metabolism during chronic renal disease are not thought to be entirely resolved 
by dialysis.72  
 
Lastly, single case reports of terminal patients with multiple organ failure (MOF) have also documented 
extremely elevated plasma glutamine levels. Although the mechanism behind this is unclear, reduced 
cellular integrity is suggested as a contributor.18 Recently, however, Nienaber and colleagues demonstrated 
low plasma glutamine concentrations in 75% of patients with MOF.58 Thus, both low and high 
concentrations have been observed in this group.  
Plasma glutamine and outcome during critical illness 
Several observational studies have provided valuable data on plasma glutamine concentration during 
critical illness and have established a relationship between plasma glutamine, markers of clinical condition, 
and clinical outcome. Table 1 (below) provides a summary of this research. 
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In their prospective cohort study, Oudemans-van Straaten and colleagues made the first link between 
plasma glutamine levels on admission to ICU and clinical outcome. Plasma glutamine concentrations among 
non-elective adult patients on admission to the ICU were measured on admission, and were subsequently 
categorised as low (<420 umol/l) and normal to high (≥420 umol/l). Measures of illness severity, predicted 
mortality, and hospital mortality were compared between groups. Low plasma glutamine was 
demonstrated in approximately one-third of critically ill patients, and a significant association between low 
plasma glutamine and hospital mortality was found. Age and shock as the primary diagnosis were shown to 
be predictors of low plasma glutamine. Trends toward associations between low plasma glutamine and low 
albumin, higher severity of illness scores and mortality predictions, were shown. However, these were non- 
significant. Importantly, this study was the first to demonstrate an unfavourable outcome associated to low 
plasma glutamine.24 
 
An observational study conducted in 2012 by Rodas et al. went on to describe plasma glutamine in a mixed 
cohort of critically ill adult patients on admission to ICU, in relation to clinical outcome. Plasma glutamine 
concentrations were analysed in relation to predictors of mortality and actual mortality. Forty four percent 
of patients were reported to have low plasma glutamine on admission.  The study corroborated Oudemans-
van Straaten’s findings by identifying plasma glutamine of <420µmol/l as an independent risk factor for 
post-ICU mortality. Increased mortality was also demonstrated among patients with circulating glutamine 
of >930µmol/l - suggesting that both low and high concentrations are associated with adverse effect. Rodas 
described this relationship between plasma glutamine and mortality as a U-shaped curve.59  
 
In 2016, Nienaber and colleagues, in two mixed ICU settings, explored plasma glutamine concentration on 
admission in relation to markers of infection, gender, and diagnosis. This study was the first of its kind to 
take place in South Africa, and sought to identify biomarkers that could be used as a proxy for plasma 
glutamine depletion. Plasma glutamine was shown to be normal among most patients. Depletion was 
reported among 38% of cases - a figure comparable to previous findings.24,58 This study was useful in that it 
reported on elevated plasma concentrations, which were found in 7% of patients. In addition, an important 
distinction was made between medical and surgical patients; the former demonstrating significantly lower 
plasma glutamine concentrations. A relationship with the infectious marker C-Reactive Protein (CRP) was 
established, and a critical CRP cut-off was identified, above which plasma glutamine was low. It was 
suggested that this be investigated further as a potential proxy for plasma glutamine, to be used in 
combination with a holistic assessment of individual patients.58   
 
In the same year, Buter and colleagues investigated differences in plasma glutamine concentrations 
between elective and non-elective admissions from a cohort of mixed ICU patients. The study was unique 
in that plasma glutamine was measured on admission and daily throughout ICU stay. Sixty five percent of 
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patients admitted to the ICU had low plasma concentrations, which is the highest reported prevalence of 
glutamine depletion to date. Plasma glutamine concentrations among non-elective patients on admission 
and on day one were found to be significantly lower when compared to elective patients, and appeared to 
remain lower throughout the course of ICU stay. Links between plasma glutamine, severity of disease, and 
the presence of infection were also made.60  
 
Another study worth mentioning (not included in Table 1, below) is that of Perez-Barcena and colleagues. 
This randomised, double-blinded, multi-centre trial investigated the efficacy of supplemental parenteral 
infusions among trauma patients, but was unique in that it measured plasma glutamine on admission, on 
day six of ICU stay, and also investigated plasma glutamine in relation to clinical outcome. The study found 
that 60% of trauma patients were glutamine deplete on presentation to ICU, and 48% remained so six days 
later, despite supplementation. Low plasma glutamine on day six was associated with increased infection, 
and longer ICU and hospital stay.66   
 
The early observational work by Oudemans-van Straaten et al.24 and Rodas et al.,59 which identified low 
plasma glutamine as an independent risk factor for mortality, led to the growing premise that many 
critically ill patients are glutamine deplete and require supplementation. In essence, these studies built the 
rationale for glutamine supplementation during critical illness.18 
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Table 1: Observational research on plasma glutamine in critically ill adults 
Reference  Design Subjects Observation Outcomes Plasma glutamine- related results 
Oudemans-van 
Straaten et al. 
(2001)                       
PG depletion and 









PG* concentration was 
measured within 24 hours 
of admission and was 
dichotomised as low 
(<420umol/l) and normal to 
high (≥420umol/l) 
PG in relation to hospital 
mortality, severity of disease, 
predicted mortality, and 
standardised mortality ratio 
(using APACHE II, SAPS II, MPM 0 
and 24) 
1. Mean PG was 523umol/l (range 220-1780umol/l) 
2. Low plasma glutamine was identified in 31% of patients and was 
associated with higher hospital mortality (p = 0.01), age (p = 0.03), and 
the diagnosis of shock 
3. Trends existed for associations between low PG and lower albumin and 
higher severity of disease and predicted mortality 
4. High PG was associated with increased CK 
Rodas et al. (2012)                          
Glutamine and 











and trauma  
PG and glutathione 
concentration were 
measured within 48 hours 
of admission. PG was 
dichotomised as  
<420umol/l and ≥420umol/l  
PG and glutathione in relation to 
ICU and post ICU all -cause 6- 
month mortality and predictors 
of mortality (APACHE II, SOFA) 
1. 44% of patients had low PG on admission 
2. Both low (<420umol/l) and high (>930umol/l) PG were found to be 
independent risk factors for post ICU all -cause 6-month mortality (p = 
0.029 and p = 0.043 respectively) 
3. Patients with PG <420umol/l had higher mortality compared to those 
with PG > 420umol/l (p = 0.037) 
4. PG was unrelated to mortality risk scoring and LOS 
Buter et al. (2016)      
Plasma glutamine 
levels in patients 
after non-elective 









elective (n = 
88) and non- 
elective (n = 
90) 
admissions 
PG concentration was 
measured on admission and 
daily throughout ICU stay 
PG in elective versus non-elective 
patients, PG change over time, 
PG in relation to severity of 
disease (APACHE IV) and 
prevalence of ICU infections  
1. 65% of patients were glutamine deplete on admission (34% of elective 
and 74% of non-elective admissions) 
2. PG on admission was significantly different between elective (median 
430umol/l [IQR 330-550umol/l]) and non-elective admissions (median 
250umol/l [IQR 90-370umol/l]), p <0.001  
3. PG remained higher in elective patients over the course of ICU stay 
4. A positive correlation between PG and APACHE IV was shown                 
(p <0.001) 
5. PG was significantly lower among those with infection (p <0.001) 
Stellenbosch University  https://scholar.sun.ac.za





Nienaber et al. 
(2016)                  
Prevalence of 
glutamine 
deficiency in ICU 








60 mixed ICU 
patients 
PG concentration was 
measured on admission. 
Low PG defined as 
<420umol/l, and high PG as 
>930umol/l  
PG in relation to infectious 
markers (Il-6 and CRP), gender, 
and diagnosis  
1. Median PG on admission was normal at 497umol/l (IQR 387-644umol/l) 
2. 38% of patients had low PG and 7% had high PG on admission 
3. PG was unrelated to gender 
4. A significant difference in PG between medical (median 475umol/l [IQR 
372-627umol/l]) and surgical patients (median 515umol/l [IQR 468-
782umol/l]) was shown (p = 0.042) 
5. PG was inversely correlated to IL-6 (p <0.05) and CRP (p = 0.08) 
6. A CRP cut off of 95.5mg/l was identified, above which PG was low 
APACHE II: Acute Physiology and Chronic Health Evaluation score; CK: Creatine Phosphokinase; CRP: C Reactive Protein; ICU: Intensive Care Unit; Il-6: Interleukin-6; LOS: Length of Stay; MPM: 
Mortality Probability Model; PG: Plasma Glutamine; SAPS: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment 
* PG measured as the sum of plasma glutamine and glutamic acid 
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Glutamine supplementation was first studied in the 1980s. Several randomised controlled trials (RCTs) 
administered parenteral glutamine as a single amino acid or as the more stable dipeptide at doses of 10-12 
g/day, with the goal of establishing if this prevented depletion during critical illness, and/or had any bearing 
on clinical outcome.8,9,74 These studies precipitated many more, which seemed to confirm a beneficial 
effect of supplemental glutamine via the parenteral route and indicated amelioration of plasma glutamine 
depletion during the diseased state.75 Improvements in intestinal barrier function and GALT, as well as 
enhanced production of short life proteins required during me tabolic stress were shown.15 Furthermore, 
reductions in infectious morbidity,10,75,76 mortality,10,25,76 and ICU10 and hospital stay76 were demonstrated 
by meta-analyses among patients who received glutamine supplementation.  
Enteral versus parenteral glutamine 
Clinical benefit has been attributed largely to parenteral provision of glutamine.25,57,77 Although l- glutamine 
is omitted from standard parenteral solutions due to poor solubility and degradation during heating 
(affecting the stability of the solution), dipeptides containing glutamine offer a more soluble and stable 
form of the amino acid, which can be administered parenterally.11 
 
Administration of glutamine via the enteral route has produced less convincing results in most patient 
groups, with meta-analyses showing no obvious clinical advantage.75,78 Some evidence does, however, 
support enteral supplementation. Reduced ICU and hospital length of stay (LOS) have been shown among 
burns and mixed ICU patients receiving glutamine via the enteral route, and reduced mortality has also 
been shown among burns patients.12 This may be explained by the fact that enteral functioning is to some 
degree preserved in these patients when compared to other critically ill patients with sepsis or shock, so 
allowing for absorption of the amino acid.26 The notion that gastrointestinal availability of glutamine 
influences efficacy of supplementation is further supported by the fact that enteral administration of 
glutamine has been shown to only marginally increase plasma glutamine levels in most critically ill patients, 
whereas parenteral supply results in an immediate increase in plasma concentration.18  
International guidelines and dosage 
On the back of such promising clinical results, glutamine supplementation among critically ill adults was 
until recently considered safe and prudent practice - used as a means to meet increased demand for the 
amino acid during hyper-catabolism. This was reflected in several international guidelines recommending 
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routine supplementation. In 2009, the American Society of Parenteral and Enteral Nutrition (ASPEN) 
recommended a routine enteral dose of 0.3-0.5 g/kg/day of glutamine for all burns, trauma, and mixed ICU 
patients. This was largely based on the nutrient’s trophic effect on the gut and the consequent 
maintenance of the intestinal barrier.12   
 
In the same year, the European Society for Clinical Nutrition and Metabolism (ESPEN) recommended 
intravenous doses of 0.2-0.4 g/kg/day l-glutamine (0.3-0.6 g/kg/day of glutamine containing dipeptide) for 
all critically ill adults receiving parenteral nutrition - suggesting that this become the standard of care. This 
guideline made reference to extensive evidence garnered over the previous decade demonstrating clinical 
benefit from parenteral provision of glutamine, and noted that no harmful effect had been shown to 
date.11  
Based on data demonstrating elevations in plasma glutamine among certain subgroups of the critically ill, 
both international guidelines11,12 and the manufacturer of parenteral glutamine dipeptides do not 
recommend supplementation for patients with renal or hepatic insufficiency.18 
 
In their review of 36 clinical trials, Kim and Wischmeyer also provided guidance on the dosage of glutamine, 
suggesting that optimal clinical benefit is associated with doses of 0.35-0.5 g/kg. In addition, the pair 
recommended that glutamine be supplemented within the first 48 hours of ICU admission, and continued 
for a minimum of five days.25 
SIGNET (Scottish Intensive care Glutamine or seleNium Evaluative Trial)  
A study conducted in 2011 by Andrews and colleagues cast some doubt on the routine use of parenteral 
glutamine supplementation. This double-blinded RCT aimed to investigate the effect of parenteral 
glutamine and selenium supplementation on infection and mortality among critically ill adult patients. Te n 
critical care units in Scotland participated in the study, including a total of 502 patients, all whom required 
parenteral nutrition. Participants were randomised to receive 20.2 g glutamine per day or 500 ug selenium 
per day, or both, for a period of up to seven days. The study showed no significant effect of glutamine 
supplementation on infection rate and on six-month mortality. In addition, no effect was demonstrated on 
ICU or hospital LOS, duration of antibiotic use, and on the modified SOFA (Sequential Organ Failure 
Assessment) scores.79 This study was, however, subsequently criticised for the low dose of glutamine 
prescribed, and for not reporting on the dosage actually received by participants. The short duration of the 
treatment period was also seen as a shortcoming of the study.18  




In their double-blinded RCT, van Zanten et al. went on to investigate the effect of immune modulating 
nutrients among a group of ventilated critically ill adults. Three hundred and one patients across 14 centres 
were randomised to receive a high protein enteral  feed enriched with glutamine, Omega 3 fatty acids, and 
antioxidants, or an isocaloric high protein feed. Baseline plasma glutamine was measured and was found to 
be low among both the intervention (365 ± 161 umol/l) and control groups (365 ± 136 umol/l), with no 
between group differences identified. Among the intervention group, average glutamine intake was 0.28 
g/kg, lower than the recommended dose. The study found no significant differences between the incidence 
of infection, infectious subtypes, SOFA scores, ICU and hospital LOS, and the duration of mechanical 
ventilation. A significant increase in six-month mortality was, however, shown in the medical subgroup of 
the intervention arm, inferring a harmful effect of high protein immune -modulating enteral nutrition 
containing a relatively low dose of glutamine. These findings once again suggested a cautious approach to 
glutamine supplementation.80 However, in their post-hoc safety analysis, Hofman et al. concluded that the 
harmful effect observed in the MetaPlus study was mediated by an increase in the ratio of Omega 3 to long 
chain fatty acids, and was unrelated to glutamine.81   
REDOXS (Reducing Deaths due to Oxidative Stress) trial 
Routine glutamine supplementation was further challenged by the REDOXS trial. This multi-centre, double-
blinded RCT reported increased in-hospital and six-month mortality among 1218 critically ill adult patients 
receiving supra-physiological doses of glutamine. Patients were randomised on admission to receive 
enteral and parenteral doses of glutamine (0.6-0.8 g/kg/day), antioxidant supplementation, a combination 
of both, or a placebo.13  
 
This trial differed from previous research by administering the highest dose of glutamine (>0.5 g/kg/day) to 
date to a particularly inclusive group of patients. Usually excluded from glutamine trials for concern over 
toxicity, patients with acute liver and renal failure, many of whom were in shock, were included in this 
cohort.19 In fact, one-third of study participants had renal dysfunction. This contravened current clinical 
guidelines on the use of glutamine as a supplement in terms of both dosage and  patient profile.15 The 
intervention was also the first to supplement enteral and parenteral glutamine simultaneously.17 Based on 
the blinding and randomisation procedures, the international, multi-centre nature of the trial, large sample 
size, and the intention-to-treat analysis, the external validity of these findings are considered high.13 
Because of its novel approach, however, the trial could not negate previous findings of benefit associated 
with glutamine supplementation, but did raise questions over the safety of this practice.15 
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 Criticism of the REDOXS study 
The REDOXS trial was based on the assumption that all critically ill  patients are glutamine deplete.14 In 
reality, plasma glutamine was not consistently low in a small subset of patients (n = 66) at baseline and at 
days four and seven. In fact, 15% of these patients demonstrated high plasma glutamine concentrations.13 
Furthermore, no information regarding clinical outcome was published for this subgroup for whom plasma 
glutamine was measured.18 Arguably, the exploratory dose-finding study conducted prior to the trial would 
have been an opportune time to investigate plasma glutamine in this population to inform the subsequent 
intervention.  
 Post REDOXS uncertainty 
Post REDOXS, significant uncertainty over the use of routine supplementation arose among clinicians 
worldwide.15 Questions surrounding pharmacological versus nutritional dosage of glutamine, enteral versus 
parenteral administration versus both, and over the supplementation of pati ents with MOF versus those 
with moderate risk of mortality, have been asked.18 
Post REDOXS meta-analyses 
In order to clarify the sudden controversy surrounding glutamine supplementation, three noteworthy 
meta-analyses were conducted between 2013 and 2014. In 2013, Bollhalder and colleagues77 included 40 
RCTs in their analysis, which involved 3107 critically ill and post-surgical patients. The analysis included the 
SIGNET study of Andrews et al.,79 but excluded the REDOXS study of Heyland and colleagues.13 The analysis 
found a significantly lower infection rate and hospital LOS among patients supplemented with parenteral 
glutamine. When studies which supplemented >0.2 g/kg/day glutamine (in keeping with clinical guidelines 
on the use of intravenous glutamine) were extracted, the authors also found a significant reduction in 
short-term mortality among all patient groups.77 
 
In 2014, Wischmeyer et al. performed a meta-analysis of RCTs conducted between 1997 and 2013, which 
focused on parenteral glutamine supplementation as part of nutritional support. Twenty six trials 
(excluding the REDOXS study), equating to 2484 critically ill patients, were included. Meta-analysis found 
significant improvements in hospital mortality and LOS, with a strong trend towards reduced infectious 
complications, length of ICU stay, and overall mortality among patients receiving parenteral glutamine 
supplementation. The group concluded that parenteral glutamine supplementation, when given alongside 
adequate nutrition support, is associated with significant clinical benefit.17 
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In their Cochrane review, Tao and colleagues sought to assess the effect of glutamine supplementation 
among critically ill adult patients. Data from 53 trials including 4671 patients were analysed. The group 
concluded that there is moderate evidence to support reduced infection and length of time spent on 
mechanical ventilation as a result of glutamine supplementation. Low quality evidence for glutamine 
supplementation reducing length of hospital stay was reported, and no conclusive evidence was found to 
suggest that glutamine supplementation influences mortality or ICU LOS.82 
 
More recently, in 2017, Stehle and colleagues conducted a meta-analysis with the goal of resolving the 
controversy surrounding glutamine supplementation. The authors criti cised previous meta-analyses given 
their inclusion criteria, arguing that studies using free glutamine and those administering the more stable 
dipeptide should not be included in the same analysis due to discrepancies in kinetics , and therefore in 
dosage. In addition, the heterogeneity of patients included in two of the most recent meta-analyses was 
also questioned.15 Bollhalder et al.77 and Tao et al.82 included both critically ill and post-surgical patients. 
This, Stehle and colleagues argued, may have introduced bias into their results regarding clinical outcome. 
In order to overcome these shortfalls, the group conducted an analysis using strict eligibility criteria for RCT 
inclusion. Only studies testing clinical outcome among patients without renal or hepatic failure, who were 
haemodynamically and metabolically stable, were included. In addition, only studies using supplemental 
glutamine dipeptide at doses based on current guidelines (0.3-0.5 g/kg/day, at less than 30% of prescribed 
nitrogen intake) via the parenteral route, in combination with the provision of adequate nutrition , were 
considered. Thus, both the REDOXS and SIGNET RCTs were excluded from this meta-analysis.15  
 
Fifteen RCTs met the above inclusion criteria - involving a total of 842 patients. Meta-analysis revealed 
significant reductions in infectious complications, duration of mechanical ventilation, hospital and ICU LOS, 
and in-hospital mortality among patients supplemented with glutamine dipeptide via the parenteral route. 
No difference in ICU mortality was demonstrated between groups.15  
 
Despite these meta-analyses, questions still remain over the use of glutamine supplementation in critically 
ill adult patients. In his 2015 commentary, Wernerman pointed out several reasons why meta-analyses 
have been unable to provide clarity on the subject. The first problem is that patients who are glutamine 
deplete have not been fully investigated. As such, the mechanism of hypoglutaminaemia and its association 
with mortality is not properly understood. Without a clear picture of this mechanism, meta-analyses cannot 
provide definitive answers. Heterogeneous patient groups and between study differences in dosage, 
supplementation period, route of administration, and the combination of nutrients supplemented , also 
make comparison very difficult.16   
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Werneman also made the point that a clear distinction should be made between supplementation and 
repletion in intervention studies. The former implies that patients with normal plasma concentrations are 
supplemented with glutamine, and the latter that patients who are glutamine deplete receive the 
nutrient.16 Failure to take heed of this important distinction may account for the adverse f indings of recent 
interventions16 - particularly given the link that established between elevated plasma glutamine and 
mortality.59 In short: a lack of understanding of the mechanisms of potential harm and benefit of glutamine, 
and of which patients require it and why, have made interventions up until this point potentially hazardous.  
Understanding plasma glutamine 
Wernerman argued that post REDOXS, it is clear that when given in pharmacological doses to a 
heterogeneous group of patients with a high risk of mortality, who are receiving inadequate nutrition, 
glutamine supplementation may well be harmful. However, he suggested that a targeted approach to 
supplementation may still be warranted given the wealth of evidence to support this, but stressed that 
basic research to gain a deeper understanding of patients’ plasma glutamine concentration is required , 
before supplementation can be considered.18   
 
Surprisingly few studies have investigated plasma glutamine as an indicator for supplementation, with only 
two interventions having measured plasma glutamine at baseline.66,80 The unexpected finding by Rodas and 
colleagues59 that both low and high plasma glutamine concentrations may be associated with increased 
mortality prompted calls to review current supplementation practices, and highlighted the need for a 
greater understanding of glutamine status within specific patient groups.19 As has rightly been pointed out, 
it would not be ethical to conduct intervention studies going forward without first monitoring and 
understanding plasma concentrations.18  
Glutamine in children 
There is limited evidence for the use of glutamine supplementation in paediatrics. Even less data is 
available on plasma glutamine concentrations within this group. As such, the role of glutamine in children 
requires further scrutiny.20 In addition to the physical demands of growth, development, and illness, 
hospitalised children are at increased risk of infection and malnutrition.83 Focused research within this 
vulnerable group is therefore important.  
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Glutamine supplementation in children 
The systematic review conducted in 2011 by Mok and Hankard provides the most comprehensive overview 
of clinical studies examining the effects of enteral and parenteral glutamine supplemen tation among 
infants and children.20 Although clinical benefits have been reported in certain subgroups of children 
receiving glutamine, results have thus far been inconsistent.84  
 
Several RCTs investigating glutamine supplementation in premature or low birth weight infants have 
reported reduced incidence of hospital-acquired sepsis and atopic dermatitis.20 However, repeated meta-
analyses have, to date, failed to demonstrate consistent clinical benefit within this population.85–88 More 
recently, the effect of enteral glutamine supplementation on brain growth and outcome within a cohort of 
102 preterm infants (<32 weeks gestation) was studied. The group found significantly fewer neonatal 
infections, as well as increased head circumference in the first year of life among those who received 
glutamine.89 Within the same cohort, longitudinal benefit was also demonstrated among infants receiving 
glutamine. Significant increases in structural volume of the brain stem, white matter, and the hippocampus 
were shown at eight years of age; an effect which was thought to be mediated by fewer infections during 
the neonatal period. Interestingly, no differences in cognitive and motor functioning or behavoiur were 
demontrated between groups at school age.90 Because glutamine has the potential to benefit many facets 
of neonatal care - including growth and development, sepsis and atopy prevention,  and gastrointestinal 
integrity - its role in preterm nutrition requires further attention.  
 
Few high-quality trials exist for specific groups of older infants and children. The use of glutamine following 
gastrointestinal surgery has garnered interest as a means to promote intestinal adaptat ion. However, 
meta-analysis of two small RCTs involving infants with gastro-intestinal disease found insufficient evidence 
to confirm clinical benefit.91 Although several case-series reports have indicated improvements in growth,92 
intestinal absorption,92,93 and stool frequency92 among patients with short bowel syndrome (SBS), firm 
conclusions cannot be drawn without more rigorous research in this area. Glutamine supplementation 
among paediatric patients with Crohn’s Disease has also been investigated as a means to attenuate 
catabolism and induce remission.20 However, reports from an RCT conducted on 15 children with active 
Crohn’s disease found no benefit in remission rates, intestinal permeability, and micronutrient profiles. In 
fact, patients who were supplemented with glutamine demonstrated poorer outcomes with regards to the 
Crohn’s disease activity index94 and nutritional status.94–96 This RCT was one of two studies included in a 
recent Cochrane review, which concluded that insufficient evidence exists to support glutamine 
supplementation as a means to induce remission among patients with Crohn’s disease.97   
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Results from RCTs are also conflicting with regard to enteral glutamine supplementation during diarrhoeal 
disease and malnutrition, with some trials demonstrating shorter duration of diarrhoea 98 and 
improvements in intestinal barrier function.99 More recently, oral glutamine supplementation during 
diarrhoeal disease was re-examined in an RCT of 138 Ugandan children aged two to 60 months admitted to 
hospital for persistent diarrhoea. No improvement in outcome was demonstrated among participants who 
received supplementation.100  
 
Although an in vitro study has demonstrated improved immune capability (bactericidal function) of 
glutamine-exposed neutrophils isolated from paediatric patients post burn injury,101 conclusive evidence 
from human trials for the use of glutamine in burns is lacking.102 In a small double-blinded, randomised 
crossover trial, Sheridan and colleagues measured plasma glutamine in children (n = 7) with severe burns, 
following 48-72 hours of enteral glutamine supplementation. Plasma glutamine increased moderately but 
non-significantly with glutamine supplementation (600 ± 0.0 umol/l) when compared to an isonitrogenous 
enteral control (400 ± 0.0 umol/l), and whole body protein sparing was not demonstrated.103 This is the 
only RCT to have assessed glutamine supplementation in children with burn injuries to date.104 
 
Promising results have been shown for oral glutamine supplementation in oncology, with several RCTs 
reporting reduced severity and duration of oral mucositis in children undergoing chemotherapy, 105 bone 
marrow,106 or stem cell transplantation.107 Other benefits attributed to glutamine supplementation include 
reductions in parenteral nutrition usage and associated costs, and also in opiate use.20 Although significant 
benefit has not been consistently demonstrated across all available studies, enteral glutamine doses of up 
to 0.65 g/kg/day have been reported to be safe and well tolerated among paediatric oncology patients.108  
 Limitations of existing research 
Definitive answers regarding the use of glutamine in children have been undermined by a simple lack of  
research as well as by methodological limitations within existing studies.84 For example, despite adopting 
rigorous experimental designs, most trials - by means of sample size - were underpowered to detect subtle 
differences in clinical outcome.20 In trials where clinical outcome was the primary endpoint, this may have 
compromised internal validity. In addition, limited sample size would have threatened the external validity 
of this research.109 
 
Reduced statistical power would also have increased the likelihood of Type II error, which raises concerns 
over the safety and therefore the ethics of these interventions.110 As yet, no adverse effects on morbidity 
or mortality have been associated with glutamine supplementation in children; however, these may have 
been overlooked by Type II error.111 This issue of safety was raised by Heyland and Dhaliwal, who 
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acknowledged that the dose-finding trial conducted prior to the REDOXS study was underpowered to 
detect changes in mortality.14 This held serious consequences for the intervention which followed.  
 
Meta-analysis of RCTs is made difficult by heterogeneous cohorts and practical differences in the use of 
glutamine. Studies on glutamine supplementation in trauma112 and burns113 patients included mixed 
samples of children and adults. In addition, those involving infants undergoing gastrointestinal surgery 
included a variety of diagnoses - thereby limiting the application of findings to specific age or patient 
groups.114 The route of administration and the relative dosages of glutamine have varied markedly between 
interventions, with the duration of supplementation ranging from two103 to seven days113 among burn and 
trauma patients, to one to two years in SBS.93 This makes it difficult to separate the effects of dose and 
time on clinical outcome. In many cases, glutamine was administered in combination with other immune-
modulating nutrients, making it difficult to isolate the effects of the single nutrient.112,113  
 
As a result of such disparity, the role of glutamine in paediatrics remains undefined. This, combined with 
newfound concerns over safety, suggest that the glutamine status of children must be further understood 
before large-scale interventions can be ethically and safely undertaken.20   
Plasma glutamine in children 
 Data from intervention studies 
Data on circulating levels of plasma glutamine in paediatric populations is scarce, with few interventions 
having described plasma glutamine levels prior to supplementation.  
 
While the work done in 2004 by Sheridan and colleagues provided useful provisional data on plasma 
glutamine levels in children with burns, patients were recruited well into their hospital stay - meaning that 
plasma levels were not reflective of glutamine status during acute injury . 103 Although crossover designs (in 
which patients form their own control) reduce the effect of confounding variables, this study’s external 
validity was limited by its small sample size.109 The crossover design also raises the possibility of a carry-
over effect, whereby glutamine administered in the intervention phase may have exerted an effect in the 
control phase. Conversely, the short intervention phase may have been insufficient to prompt a significant 
plasma glutamine response.20 Both possibilities question the internal validity of the study.  
 
In their intervention study, Chaloupecky et al. investigated the plasma amino acid profiles of infants 
following cardiac surgery. Patients were randomised to receive glucose intravenous support, or parenteral 
nutrition containing amino acids. Plasma glutamine was low (287 ± 86.4 umol/l and 278.3 ± 95.5 umol/l) in 
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both intravenous fluid and parenteral groups respectively on day two post-surgery. Interestingly, plasma 
glutamine concentration had normalised by day seven post-operatively in patients from both groups.115 
 Data from observational studies 
Observational studies, although few in number, have provided valuable information on plasma glutamine 
concentrations among critically ill  children. A summary of the observational studies in paediatrics is 
provided in Table 2 (below).  
 
The early observational study by Villares et al. investigated the amino acid profile (inclusive of glutamine) of  
post-operative patients with congenital heart disease. Plasma aminogram analyses were conducted prior to 
surgery, and on day one, three, and seven post-operatively. On average, plasma amino acids were found to 
be normal at baseline, significantly reduced after surgery, and slowly normalised over time. Plasma 
glutamine was found to be low on day one and three post-operatively. Glutamine was, however, unique in 
that it was the only amino acid to remain low on day seven - demonstrating a much slower recovery.116 
 
The clinical audit conducted by Marino and colleagues was one of the few studies to have described plasma 
glutamine (in relation to HSP70) in a specific group of critically ill children, without the provision of 
glutamine. Data on disease severity and clinical outcome were collected retrospectively from the records of 
children admitted to intensive care with acute meningococcal disease, and from patients post-discharge. 
Glutamine concentrations were determined using stored plasma samples. The audit demonstrated 
significantly lower plasma glutamine during the acute phase of illness when compared to convalescence. 
Inverse relationships were found between plasma glutamine and markers of inflammation, LOS, and clinical 
outcome, suggesting, as in adult studies, an association between low plasma glutamine and disease 
severity.21 
Ekmark and colleagues went on to investigate plasma glutamine concentrations in patients admitted to a 
Paediatric Intensive Care Unit (PICU) in relation to clinical outcome. This study found that 40% of patients 
were glutamine deplete when compared to healthy controls. In addition, low plasma glutamine on 
admission to PICU was significantly associated with the development of MOF. Because mortality in the 
paediatric population is low, MOF was used in this study as a proxy for clinical outcome using the PELOD 
(Paediatric Logistic Organ Dysfunction) score - calculated on admission and again on day five of PICU stay. 
Interestingly, plasma glutamine concentrations were found to normalise in most patients who stayed 
longer than five days in the intensive care unit.22 
 
These studies established an important precedent for future research by describing plasma glutamine in 
paediatric patients without intervention. Their demonstration of significant associations between plasma 
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glutamine and clinical outcome has highlighted the need for similar observational research among children 
in different contexts.  
Motivation for the current study 
Glutamine is considered a conditionally essential amino acid during periods of critical illness. As such, 
supplementation of the nutrient has become commonplace among adult ICU populations. Recent concern 
over the safety of glutamine supplementation has, however, highlighted the need for focused research on 
plasma glutamine levels in specific patient groups.  
There is limited evidence for the use of glutamine supplementation in children, with even less data 
available on plasma concentrations within this group. Two observational studies have , however, 
demonstrated associations between low plasma glutamine and increased inflammatory markers,  length of 
hospital stay,21 and incidence of MOF, suggesting that, as in adults, plasma glutamine may be a useful 
marker of clinical outcome among critically ill children.22 A limitation within existing research is the 
different time points at which plasma glutamine has been measured.  While most studies have investigated 
plasma glutamine on admission to PICU,21,22 repeat measurements have been conducted on day three 116 or 
five22 of hospital stay, or later during convalescence21. As a result very little is known about the degree to 
which plasma glutamine changes, particularly within the acute stage of critical illness. It is clear that the 
glutamine status of critically ill children must be further understood - in terms of plasma concentration and 
the degree of change which occurs within a specific time period - before intervention studies can be 
undertaken. Exploratory studies such as this one provide the unique opportunity to generate new 
knowledge within a field in which very little is known. 
  




Table 2: Observational research on plasma glutamine in critically ill children 
Reference  Design Subjects Observation Outcomes Plasma glutamine-related results 
Villares et al. (2008) 
Plasma aminogram in 





55 children < 3 years 
old with CHD 




measured at baseline, 
on day 1, 3, and 7 
post- operatively 
Plasma amino acid 
concentration at each time 
point in relation to 
nutritional status and 
biochemical indices 
1. Plasma amino acid concentrations were normal at baseline 
2. Concentrations of all amino acids decreased significantly 
after surgery (p <0.05) with a slow trend towards 
normalisation 
3. On day 3, glutamine, isoleucine, alanine, arginine, and 
threonine remained low (p < 0.05) 
 4. Glutamine was the only amino acid to remain significantly 
low a week post-surgery 
5. Nutritional status and amino acid concentration were 
unrelated 
Marino et al. (2014)       
Glutamine depletion 
and heat shock 
protein 70 in children 
with meningococcal 
disease 
Clinical audit 143 infants and 
children diagnosed 
with meningococcal 
disease on admission 
to PICU, 73 
convalescent 
children post 
discharge, 35 healthy 
controls 
Stored plasma was 
used to measure PG*, 
HSP70, and the 
inflammatory 
mediators Il-6, Il-10, 
and TNF ἀ 
PG and HSP70 at each time 
point and in relation to each 
other, clinical indices, 
inflammatory mediators, 
mortality risk (PRISM), 
glutamine intake, clinical 
outcome  
1. PG was significantly lower on admission (mean 310umol/l ± 
130umol/l) compared to convalescence (mean 400umol/l ± 
140umol/l), p < 0.001 
2. PG was 52 % and 26% below the normal range on admission 
and during convalescence respectively 
3. PG was inversely related to PICU LOS (p < 0.001), duration 
of ventilation (p < 0.001), lactate (p < 0.001), and CRP              
(p < 0.001) 
4. PG was positively correlated to glutamine intake (p = 0.023)  









149 infants and 
children admitted 
consecutively to a 
mixed medical and 
surgical (excluding 
cardiac) PICU, 60 
healthy controls 
PG and PELOD were 
measured within 48 
hours of admission 
and on day 5 of PICU 
stay 
PG concentration at each 
time point and in relation to 
PELOD score 
1. Median PG on admission was 446umol/l (IQR 323- 
556umol/l) which was lower than healthy controls (p < 0.001) 
2. 40% of patients were glutamine deplete on admission 
3. Low PG was associated to the development of MOF             
(p = 0.001) 
4. For most children PG normalised by day 5 
5. Patients with low PG tended to have a longer PICU stay  
HSP70: Heat Shock Protein 70; Il-6: Interleukin-6; Il-10: Interleukin-10;  LOS: Length of Stay; MOF: Multiple Organ Failure; PG: Plasma Glutamine; PRISM: Paediatric Risk of Mortality; TNF 
ἀ: Tumour Necrosis Factor ἀ   *PG was reported as the sum of PG and glutamic acid with a normal cut off of ≥600umol/l 
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In light of clear gaps in existing knowledge regarding plasma glutamine in children, and considering the 
need for exploratory research within this group, the following question was raised: 
What is the plasma glutamine concentration of children on admission to PICU and during the first two days 
of PICU stay? 
Aim 
To investigate plasma glutamine concentration among patients on admission to PICU and on day two  of 
PICU stay - in relation to clinical condition and outcome.   
Objectives  
1. Describe plasma amino acid concentrations, inclusive of glutamine, on admission to PICU and on day 
two of PICU stay.  
2. Identify associations between plasma glutamine concentration and clinical condition on admission to 
PICU, nutritional status, and nutritional intake. 
3. Identify associations between admission plasma glutamine concentration and PICU and hospital LOS.  
4. Identify associations between plasma glutamine concentration and mortality . 
Null hypotheses 
H01 =  Plasma amino acid concentrations do not change during the first two days of PICU stay . 
H02 =  No relationship exists between plasma glutamine concentration and clinical condition on admission 
to PICU.   
H03 =  No relationship exists between plasma glutamine concentration and the nutritional status 
(determined by age-related Z scores) of children in PICU  
H04 =  No relationship exists between plasma glutamine concentration and dietary protein or energy 
intake during the first two days of PICU stay. 
H05 =    No relationship exists between plasma glutamine concentration and PICU or hospital LOS. 
H06 =  No relationship exists between plasma glutamine and mortality. 
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Study design and method 
A descriptive, cross-sectional study was carried out.  
Target population  
Due to the cross-sectional nature of the study, all patients admitted to the Red Cross War Memorial 
Children’s Hospital (RCWMCH) PICU between 06 November and 05 December 2016, were eligible for 
inclusion in the study.  
 
RCWMCH is a tertiary centre that provides intensive care to infants and children from within the public 
healthcare sector in Western Cape Province, South Africa. It also accepts patients requiring specialist 
services from further afield in South Africa and neighbouring African countries .117  
 
RCWMCH’s PICU admits medical and surgical patients aged 0-18 years, most of whom are under the age of 
two years. At the time of study, the unit had a capacity of 22 beds, and admitted an average of 80-100 




All patients admitted to RCWMCH PICU between 06 November and 05 December 2016 were re cruited, 
provided that: 
- they were below the age of 18 years 
- written informed consent was obtained from a parent or legal guardian within 48 hours of 
admission 
- blood sampling was possible within 24 hours of admission 
Exclusion criteria 
 
Patients were excluded from the study if: 
- they were 18 years or above 
- written informed consent was not obtained from a parent or legal guardian within 48 hours of 
admission 
- routine phlebotomy was not required during PICU admission 
- blood sampling was not possible within 24 hours of admission 
- they had a known haemoglobin level of below 7 g/dl at the time of blood sampling 
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- they were deemed too unstable for additional blood sampling by the medical team (any patient 
could be excluded from the study at the discretion of the attending clinician)  
Sampling strategy 
Due to the cross-sectional nature of the study, consecutive sampling was used to recruit participants over a 
one-month period. During the planning phase of the study, sample size was pragmatically estimated at 75-
100 participants. This decision was based on logistical considerations such as the data collection period, 
unit occupancy, and on cost – with the expense of plasma amino acid analysis proving to be a limiting 
factor. 
Data collection 
A standard data collection sheet (Addenda C) was used to collect data. Data were collected on admission to 
PICU (referred to for the purposes of this study as day zero) and again 48 hours after admission (during day 
two of PICU stay), as well as at PICU and hospital discharge. Table 3 (below) indicates the data that were 
collected at each time point: 
 
Table 3: Data collection at each time point 
  Data Collected 
PICU 
Day 0 







Admission data PICU admission date       Medical file 
Demographics 
Age (years, months)       
Medical file 
Gender        
Diagnosis and 
illness severity 
Diagnostic category       
Medical file PIM 3 score       
HIV/TB status       
Anthropometry 
Weight (kg)      Clinical 
examination 
by dietitian 
Length/ height (cm)       first  available opportunity   
MUAC (cm)      
Biochemistry 
Plasma aminogram     Laboratory 
Albumin (g/l)     
Medical file 
CRP (mg/l)     
PCT (ng/ml)     
Lactate (mmol/l)     
Glucose (mmol/l)     
Nutrition 
Type and route of feed     
Medical file 
Volume of feed per day     
Clinical 
outcome 
Ventilation (days)      
Medical file 
Length of PICU stay (hours)      
Length of hospital stay (days)      
Mortality      
CRP: C Reactive Protein; HIV: Human Immunodeficiency Virus; MUAC: Mid Upper Arm Circumference; PIM3: 
Paediatric Index of Mortality; PCT: Procalcitonin; TB: Tuberculosis 




 Clinical condition on admission 
Diagnosis, disease severity, presence of infectious disease, and routine biochemistry were used as 
measures of clinical condition on admission to PICU. In order to strengthen the data analysis, diagnoses 
were categorised as medical, surgical (elective or emergency), or trauma – and further sub-categorised 
according to primary diagnosis. This was based on a combination of criteria outlined by Heyl and and 
colleagues13 in 2013, and on unit-specific patient profiles (as seen in Addenda C).  
 
Human immunodeficiency virus (HIV) and tuberculosis (TB) status were noted due to the region’s high 
prevalence of infectious disease among young children.118,119 Paediatric Index of Mortality 3 (PIM 3) is a 
widely accepted indicator of disease severity and mortality risk, and is part of routine practice in the unit.120 
A previous version of this tool had previously been validated in the RCWMCH setting.117 As such, PIM 3 
scores were used as a marker for illness severity in this study, from which the  probability of mortality was 
calculated. 
 Anthropometry 
Anthropometry was, where possible, conducted prior to PICU discharge. When this was not feasible, 
convalescent measurements were taken at a ward level before hospital discharge. Where oedema was 
present, anthropometry measurements were delayed until this had resolved.   
 
Weight, length or height, and mid upper arm circumference (MUAC) were used to assess nutritional status. 
All anthropometry was conducted according to international standards using cali brated equipment.121 A 
non-stretch measuring tape was used to determine MUAC in infants and children aged six months or 
above. Naked weight was measured using an electronic baby scale  for patients younger than two years, 
and an electronic scale was used for older children in light clothing. Recumbent length was measured for 
patients less than two years old using a portable length mat, and where possible standing heights were 
measured for older children using a stadiometer.  
 
Weight, length, and height measurements were plotted on World Health Organization (WHO) growth 
charts and interpreted according to standard deviation (Z) scores. Scores of <-2 or >+2 were used to 
indicate under- or over-nutrition respectively.122 Preterm infants <37 weeks gestation were excluded from 
nutritional status analyses, so as not to skew the data. Proportionality was assessed using weight-for-length 
and body mass index (BMI)-for-age charts for those aged five years or below and those older than five 
years respectively. 




For infants and children aged six months to five years, MUAC was interpreted using WHO standards, with 
measurements of <11.5 cm indicating severe acute malnutrition, and ≥11.5 - <12.5 cm indicating moderate 
acute malnutrition.122 For older children, MUAC was classified according to Mramba and colleagues’ growth 
curves, which were developed in accordance with WHO standards.123 When both were available, MUAC 
and weight-for-length or BMI-for-age categories were compared, and the most unfavourable classification 
chosen to describe each participant’s acute nutritional status.  
 Routine biochemistry  
According to PICU protocol, routine biochemical analyses are, for most patients, performed on admission. 
Following this, daily samples are collected at 05:00 – and for those who require it, additional samples are 
drawn later in the day. All phlebotomy is conducted by medical doctors.  
 
For this study, biochemical results from admission and on day two of PICU stay were collected. Where 
available, albumin, Procalcitonin (PCT) and CRP were recorded as markers of inflammation,124 and lactate 
as an indicator of inadequate tissue oxygenation and damage.125   
 Plasma amino acid analysis  
At the time of routine phlebotomy, on admission to PICU, an additional 500 ul (0.5 ml) of whole blood was 
drawn for amino acid analysis. A second blood sample of 500 ul (0.5 ml) was drawn for amino acid analy sis 
during the first set of routine bloods conducted 48 hours after admission. This took place on day two of 
PICU stay. A total volume of 1000 ul (1.0 ml) additional blood was therefore required per patient for 
research purposes. This volume complied with the Stellenbosch University Health Research Ethics 
Committee guidelines for paediatric blood-draw volumes for research purposes at a single time point.126 
Patients were excluded from further blood sampling if their haemoglobin was known to be below 7.0 g/dl 
at the time of blood draw. In addition, the medical team was encouraged to exclude patients deemed to be 
clinically unfit for additional blood sampling.  
 
Where possible, samples were drawn using an existing cannula, and were collected in heparinised vials, 
centrifuged within 30-60 minutes, and stored in the laboratory at -80○C, pending batch analysis. Once all 
samples had been collected, blood was analysed by the National Health Laboratory Service (NHLS) at 
RCWMCH Hospital, using gas chromatography.  
 
Total plasma glutamine was expressed independently, as well as by the sum of plasma glutamine and 
glutamic acid, in order to account for the breakdown of glutamine to glutamic acid during processing .21 
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Plasma glutamine of <420 umol/l was categorised as low, and >930 umol/l as high, as referenced in the 
current literature.24,59 Age-dependent reference ranges described by Blau et al. were also used to 
categorise plasma glutamine concentrations.127 Combined values of plasma glutamine and glutamic acid 
were not categorised due to the absence of established reference ranges.  
 
In order for plasma glutamine to be analysed, a full plasma aminogram was conducted. As a result, baseline 
and day two values of all amino acids were reported in this study as a matter of interest.  
 
As per laboratory protocol, blood samples were stored on site at -20○C for two months following analysis. 
At this time, the samples were dispatched to and destroyed by the external contractor - BCI Medical Waste 
Management.  
 Nutritional intake 
Feed type, route, and volume were recorded for the first 48 hours of PICU stay ( from admission until the 
end of day one). This was done in order to reflect the intake of participants in the period leading up to day 
two plasma glutamine sampling.  From this data the average daily energy and protein intake were 
calculated, compared to individual nutritional requirements, and expressed as a percentage thereof.  
  
Breastfeeding infants were excluded from dietary analysis, as daily feed volume was unquantifiable. For 
participants who received food, meal content was analysed using RCWMCH food service menus, as well as 
food composition databases from the United States Department of Agriculture (USDA)128 and the South 
African Medical Research Council (SAMRC).129  
 
Nutritional requirements for participants, from birth at term to 18 years old, were calculated using ASPEN 
guidelines on the provision of nutritional support to critically ill infants and children.130 Energy and protein 
requirements for preterm infants were calculated using recommendations established by the European 
Society of Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) 131 and by Uauy and 
Koletzko.132 The energy requirements for participants admitted with burns were calculated using an 
average of two well-established diagnosis-specific formulae from Mayes and the WHO (the latter is 
routinely doubled in the case of burns).133,134 Estimated protein requirements for these participants were 
based on the work of McCarthy.135  
 Measures of clinical outcome  
Common indicators of clinical outcome in critically ill patients were collected, including information on the 
duration of ventilation, length of PICU and hospital stay, and both in-PICU and in-hospital mortality. For the 
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purposes of this study, mechanical ventilation included all modes of respiratory support – excluding high 
flow and nasal prong oxygen. Participants who died in the PICU or on a ward level were excluded from PICU 
and hospital LOS analyses respectively.  
 
Data analysis 
For the purposes of this study, plasma glutamine on admission and on day two of PICU stay were described 
and compared. Associations between plasma glutamine and various indicators of clinical condition, 
nutritional status, nutritional intake, and clinical outcome were investigated. Where applicable, day 0 
(admission) and/or day two plasma glutamine concentrations were used for the analysis. When 
appropriate, the change in plasma concentration that occurred between day 0 and day two (referred for 
the purposes of this study as ‘glutamine change’) was also used for analysis.  
 
It has been suggested that plasma glutamine concentration should be reported as the sum of plasma 
glutamine and glutamic acid.21,24 For the purposes of this study, all statistical analyses were repeated using 
day 0 and/or day two plasma glutamine and glutamic acid, and, where appropriate, the change which 
occurred between admission and day two. The results in this dissertation focus primarily on plasma 
glutamine, but do report any significant results found using the sum of plasma glutamine and glutamic acid.  
 
Data were entered onto a prepared spread sheet in Microsoft Office Excel 2014. Data analysis was planned 
by the researcher and was performed with the assistance of a statistician using STATISTICA version 12 
software (StatSoft Inc, Tulsa, USA). Counts and percentages were used to describe categorical and ordinal 
data – and were, where appropriate, represented visually using histograms. Shapiro Wilk or Kolmogrov -
Smirnov tests were used to test for normality. Depending on the distribution of numerical data, means ± 
standard deviation (SD) and medians with interquartile range (IQR) were used as measures of central 
tendency and spread. Parametric inferential analyses were used when numerical data were normally 
distributed. 
 
Relationships between continuous variables were investigated using Pearson’s or Spearman’s correlation, 
and significant results were represented using scatterplots. Analysis of variance (ANOVA), t -tests or their 
non-parametric alternatives, were used to compare groups. A p  value of <0.05 was used to represent 








This study adhered to the ethical guidelines outlined by the Declaration on Helsinki.136 Prior to 
commencement, ethical approval was granted by the Health Research Ethics Committee, Faculty of 
Medicine and Health Sciences, University of Stellenbosch (reference S12/05/085), as well as by the 
University of Cape Town’s Faculty of Health Sciences Human Research Ethics Committee (reference 
681/2016). Permission was also sought and obtained from RCWMCH management.  
Informed consent and assent 
Written informed consent was obtained by the researcher from each participant’s parent or legal guardian 
within 48 hours of admission to PICU. The information discussed with caregivers included details of the 
study - including deferred consent for blood sampling conducted on admission, assurance of anonymity, 
expected risk and benefit, and of their right to withdraw at any time. If absent from the ward, caregivers 
were telephoned for verbal consent, and relevant paperwork was completed on presentation to hospital. If 
no informed consent had been obtained within the first 48 hours of admi ssion, the patient was excluded 
from the study – with no further blood samples drawn and no amino acid analyses conducted.  
 
Written informed consent was obtained from caregivers in their choice of English, Afrikaans, or isiXhosa, 
and a signed copy was provided in this language (Addenda A). Where isiXhosa was preferred, a registered 
nurse fluent in the language was used as an interpreter. Wherever possible, assent was obtained from 
children above the age of six years when they were well enough, and this was taken in the language of their 
choice (Addenda B). 
Confidentiality and anonymity 
Confidentiality and anonymity were ensured by allocating each patient a unique identification code which 
was used throughout the study, and also by entering data into a spread sheet accessible to only three 
members of the research team.  
Risk and benefit 
Participants and their families did not benefit directly from the study. In order to reduce the risk of 
discomfort, anthropometrical measures were delayed if the patient was ex periencing distress. Where 
malnutrition was identified, patients were referred to a dietitian for nutritional support.  
 
Drawing blood is an invasive procedure and is therefore an ethical concern. Logistical and ethical details 
regarding the blood sampling that took place during this study have been discussed above.  
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Of the 86 eligible patients, 76 were included in the final study. The reasons for exclusion are indicated in 
Figure 3 (below). No patient was deemed clinically unfit for inclusion in the study by the attending medical 
team.  
 
Figure 3: Recruitment of participants 
 
Study participants had a median age of 19 months, ranging from 33 weeks gestational age to 12 years and 
eight months old. As seen in Table 4 (below), 72% (n = 55) of participants were below the age of five years. 
Of the eight (10.5%) premature infants included, most were still <37 weeks gestation at the time of study. 
The sample consisted predominantly of males (n = 54, 71.1%), and most participants were admitted to the 
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Table 4: Demographic information (n = 76) 
    n % 
Gender Male 54 71.1 
 Female 22 28.9 
Age < 1 year 33 43.4 
 
1–5 years 22 28.9 
Preterm Total 8 10.5 
 
CGA <37 weeks 5 6.6 
 
CGA >37 weeks 3 3.9 
Admitted from Ward 45 59.2 
 
Medical emergency 20 26.3 
 
Other hospital 11 14.5 
Diagnostic category Surgery-elective 41 53.9 
 
Surgery-emergency 5 6.6 
 
Medical 24 31.6 
 
Trauma 6 7.9 




The diagnostic profile of participants was to a large extent comprised of elective surgery (n =41, 53.9%), 
followed by medical, trauma, and emergency surgery cases (Table 4).  
 
The most common primary diagnosis was cardiology (n = 36, 47.4%), followed by pulmonology (n = 11, 
14.5%), gastroenterology (n = 8, 10.5%), sepsis (n = 4, 5.3%), and burns (n = 3, 3.9%). For statistical 
purposes, participants admitted for orthopaedic, maxillofacial, oncology, nephrology, malnutrition, 
neurology, and other reasons, were grouped as ‘other’ (n = 14, 18.4%), as indicated in Figure 4 (below).  
 




Figure 4: Primary diagnosis of study participants  
Severity of disease 
Severity of disease and risk of mortality was determined using PIM 3 scores for each patient. The median 
PIM 3 score was -4.23 (IQR -4.74 - -3.21), equating to a median risk of mortality of 1.4% (IQR 0.8-3.9%). 
Infectious disease 
Table 5 (below) illustrates the burden of infectious disease among study participants  at the start of the 
study – most of whom were TB- and HIV-negative and HIV unexposed. 
 
Table 5: Burden of infectious disease (n = 76) 
    n % 
HIV status Positive 3 3.9 
 
Negative 72 94.7 
 
Unknown 1 1.3 
HIV exposure Exposed 10 13.2 
 
Unexposed 64 84.2 
 
Unknown 2 2.6 
TB status Positive  5 6.6 
 
Negative 71 93.4 
  Unknown 0 0.0 
HIV: Human Immunodeficiency Virus; TB: Tuberculosis 
 
 




Routine biochemical parameters of participants on admission are presented in Table 6 (below).  
Table 6: Routine biochemistry on admission     
  n Mean ± SD  Min- Max 
CRP (mg/l) 17 38.6 ± 85.1 0-332.0 
PCT (ug/l) 14 14.2 ± 17.1 0-61.0 
Albumin (g/l) 28 29.3 ± 9.0 9.0-44.0 
  n Median IQR Min- Max 
Lactate (mmol/l) 73 1.6 1.1-3.0 0.7-16.0 
Glucose (mmol/l) 73 7.0 5.6-8.4 0.9-20.6 
Urea (mmol/l) 76 4.2 3.3-5.7 1.1-34.4 
Creatinine (umol/l) 75 31.0 22-43.5 8.0-1039.0 
Bilirubin (umol/l) 16 10.5 5.8-45.3 2.0-145.0 
Conjugated bilirubin (umol/l) 16 3.5 1.0-11.8 1.0-30.0 
ALT (U/l) 16 25.0 17.8-48.0 1.0-30.0 
AST (U/l) 16 57.0 37.8-239.3 29.0-562.0 
ALP (U/l) 12 187.5 137.3-304 54.0-718.0 
GGT (U/l) 10 20.0 17.0-46.5 11.0-168.0 
Haemoglobin (g/dl) 73 11.4 9.9-12.7 4.9-20.8 
White cell count (x109) 73 13.3 10.4-18.8 2.0-43.5 
Platelets (x 109) 73 256.0 164.0-344.0 14.1-80.0 
ALT: Alanine Transferase; AST: Aspartate aminotransferase; CRP: C- Reactive Protein; GGT: 
Gamma-glutamyl transferase; IQR: Interquartile range; PCT: Procalcitonin; Min: Minimum; Max: 
Maximum; SD: Standard Deviation  
 
Of the 76 participants for whom blood was taken on admission to PICU, 17 had CRP and 14 had PCT 
measured as markers of infection. Of these, six (35.3%) and 10 (71.4%) had raised CRP and PCT levels 
respectively. The albumin of 28 participants was measured on admission. Because reference ranges vary 
per age group, a cut off of ≤20 g/l was used to demonstrate obviously low albumin levels. Five (17.9%) of 
these participants were shown to have low albumin.  
Clinical outcome 
Mechanical ventilation 
Fifty six participants (74.7%) received ventilation during PICU stay, for a median duration of 23.7 hours (IQR 
0-78 hours). One patient required 514 hours of ventilatory support.  
Length of stay 
Mean LOS in the PICU was 144.3 ± 239.7 hours, equating to six days. Several patients who spent less than 
24 hours in the PICU were, however, excluded from the study as blood sampling was not possible during 
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this time. Median length of hospital stay was 10 days (IQR 7-20 days), ranging from a minimum of two to a 
maximum of 88 days (n = 68). Data from deceased participants (n = 8, 10.5%) were excluded from LOS 
calculations.  
Mortality 
Eight deaths (10.5%) occurred over the duration of the study, seven of which took place in PICU and one in 
another ward.  
Nutritional status 
Most participants fell within normal parameters for weight-for-age, length/height-for-age, and weight-for-
length/height or BMI, as indicated in Table 7 (below). Thirty seven percent (n = 23) of children were 
underweight for age, and a further 24.2% (n = 15) were found to be stunted. For infants and children above 
six months of age, MUAC was also measured, which mostly fell within normal ranges for age (n = 33, 
73.3%). According to MUAC measurement alone, 17.8% (n = 8) of participants were moderately wasted, 
and 8.9% (n = 4) were severely wasted. However, when data on MUAC and weight-for-height were 
combined, 10 participants (16.1%) were moderately wasted and a further 10 participants (16.1%) were 
severely wasted – as seen in Table 7. One participant (1.3%) was admitted solely for the treatment of 






















Table 7: Nutritional status of participants on admission 
  n % 
Weight-for-age 
  Normal 39 62.9 
Moderately underweight 15 24.2 
Severely underweight 8 12.9 
Length/height-for-age 
  Normal 47 75.8 
Moderate stunting 8 12.9 
Severe stunting 7 11.3 
Weight-for-height/ BMI 
 Normal 42 67.8 
Moderate wasting 10 16.1 
Severe wasting 8 12.9 
Obese 2 3.2 
MUAC 
  Normal 33 73.3 
Moderate wasting 8 17.8 
Severe wasting 4 8.9 
Weight-for-height +MUAC   
Normal 40 64.5 
Moderate wasting 10 16.1 
Severe wasting 10 16.1 
Obese 2 3.3 
BMI: Body Mass Index; MUAC: Mid Upper Arm Circumference   
 
Nutritional intake  
The nutritional intake of participants was recorded for the first two days of PICU stay, from admission to 
the end of day one. Data on the nutritional intake of participants on day 0 and day one of PICU stay were 
available for 75 and 72 participants respectively – the detail of which is presented in Table 8 (below). One 
third of participants remained nil per mouth during the first 24 hours of admission, with 1.3% (n = 1) having 
received exclusive parenteral nutrition. During the course of day one, 55% (n = 40) had been transitioned 
onto exclusive enteral tube feeding, and 34.7% (n = 25) onto oral feeds. Only a small numbe r (n = 4, 5.5%) 
remained nil per mouth, with three (4.1%) receiving parenteral nutrition. Only one (1.4%) participant 
received no feeds at all. By the end of day one, 68 participants (94.3%) had received some enteral nutrition. 
Breast milk in the form of breastfeeding or expressed breast milk was received by 18.1% (n = 13) by the end 








Table 8: Mode of feeding 
  Day 0 (n = 75) Day 1 (n = 72) 
  n % n % 
Nil per mouth 24 32.0 4 5.5 
- NPM on exclusive PN 1 1.3 3 4.1 
PN + NGT/NJT 0 0.0 3 4.1 
Exclusive NGT/NJT 33 44.0 40 55.5 
Oral  18 24.0 25 34.7 
Received breast milk 11 14.6 13 18.1 
NGT: Nasogastric Tube; NJT: Nasojejunal Tube; NPM: Nil per mouth; PN: 
Parenteral Nutrition 
 
Of the 60 participants for whom nutritional requirements could be calculated, only 5% (n = 3) met 100% 
caloric requirements over the first 48 hours of PICU stay (day 0 to end day one), and only 6.7% (n = 4) met 
protein requirements during this time. Although 16.7% (n = 10) of participants met 66% of energy targets, 
the vast majority did not come close, with a median achievement of 30.8% (IQR 17.1-53.4%) and 36.2% 
(IQR 18.1-16.1%) of caloric and protein requirements respectively – as seen in Table 9 (below).  
 
Table 9: Nutritional intake (n = 60) 
    n % 
100% Requirements Met Energy 3 5 
  Protein 3 6.7 
66% Requirements Met Energy 10 16.7 
 




Average Intake per Day Energy (kcal) 202.3 67.3 - 378.8 
  Protein (g) 5.2 1.7 - 13.7 
Average Intake per Kilogram Energy (kcal/kg) 18.2 9.7 - 31.1 
  Protein (g/kg) 0.5 0.3 - 0.9 
% Requirements Met Energy 30.8 17.7 - 53.4 
  Protein 36.2 18.1 - 61.1 
 
Plasma glutamine  
Baseline blood samples for amino acid analysis were taken from all 76 participants on admission (day 0), 
and day two samples were drawn from those participants who were still in PICU at this time (n = 40, 52%). 
Median plasma glutamine on day 0 was 556.5 umol/l (IQR 459.5–664.5 umol/l) and on day two was 529.0 
umol/l (IQR 356.0–716.0 umol/l). The medians of the combined concentration of pl asma glutamine and 
glutamic acid were 632 umol/l (IQR 544–784 umol/l) on day 0 and 649 umol/l (IQR 456–831 umol/l) on day 
two.  




Based on reference ranges used in current literature,24,59 most participants demonstrated normal plasma 
glutamine on day 0 (n = 59, 77.6%), with this proportion reducing slightly by day two (n = 27, 67.5%) – as 
indicated in Figure 5 (below). The percentage of participants demonstrati ng low plasma glutamine 
increased over time from day 0 (n =13, 17.1%) to day two (n = 11, 27.5%). However, none of these 




Figure 5: Plasma glutamine on day 0 and day two 
 
When categorised according to NHLS reference ranges,127 plasma glutamine was again shown to be 
predominantly normal on day 0 (n = 53, 69.7%) and day two (n = 25, 62.7%) – as seen in Figure 6 (below). 
Again, no significant differences were shown within the categories of low, normal and high (p = 0.764). A 
higher proportion of participants was however shown to have high plasma glutamine on both day 0 (n = 12, 
15.8%) and day two (n = 8, 20%), when compared to the international reference ranges demonstrated in 
Figure 5.  
 




Figure 6: Plasma glutamine on day 0 and day two using laboratory reference ranges  
Plasma glutamine over time 
ANOVA testing showed no significant difference between plasma glutamine on day 0 and day two of PICU 
stay (F (1,39) = 0.21, p = 0.886). A positive relationship was, however, demonstrated between plasma 
glutamine on day 0 and day two (Spearman r = 0.38, p = 0.001), indicating an increased likelihood of lower 
plasma levels on day two if levels were low on admission (Figure 7, below). With outliers removed, this 
relationship was, however, not significant. 
 
 
Figure 7: Relationship between day 0 and day two plasma glutamine 
 
 
r = 0.38, p = 0.001 
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Aminogram results  
In order to analyse plasma glutamine concentration, a full aminogram was conducted on each blood 
sample. Table 10 (below) illustrates the measures of central tendency and spread for each of the remaining 
amino acids and describes their classification according to NHLS reference values. Significant differences in 
the plasma concentrations of alanine (p = 0.011), cysteine (p = 0.000), serine (p = 0.027), and tryptophan (p 
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Table 10: Aminogram description 
Amino acid (umol/l) Day Mean/Median SD/ IQR Low (n, %) Normal (n, %) High (n, %) 
Alanine* 0 210.5 150.0 - 308.0 20 (26.3) 45 (59.2) 11 (14.5) 
  2 168 122.0 - 220.0 16 (40.0) 21 (52.5) 3 (7.5) 
α Aminobutyrate 0 12 9.5 -16.5 21 (27.6) 54 (71.1) 1 (1.3) 
  2 13.5 8.5 - 17.5 12 (30.0) 28 (70.0) 0 (0.0) 
Asparagine 0 36.5 29.0 - 46.5 14 (18.4) 59 (77.6) 3 (3.9) 
  2 44 27.0 - 48.0 10 (25.0) 28 (70.0) 2 (5.0) 
Aspartic acid 0 7 4.5 - 8.0 7 (9.2) 66 (86.8) 3 (3.9) 
  2 7 5.0 - 9.0 2 (5.0) 36 (90.0) 2 (5.0) 
Cysteine* 0 40 ± 15.6 23 (30.3) 43 (55.3) 11 (14.5) 
  2 25 16.5 - 31.0 22 (55.0) 15 (37.5) 3 (7.5) 
Glutamic acid 0 78.5 49.5 - 127.0 2 (2.6) 31 (40.8) 43 (56.6) 
  2 78 48.0 - 125.5 3 (7.5) 15 (37.5) 22 (55.0) 
Glycine 0 183 139.5 - 240.0 7 (9.2) 59 (77.6) 10 (13.2) 
  2 179 134.5 - 256.0 4 (10.0) 30 (75.0) 6 (15.0) 
Histidine 0 59 46.0 - 72.5 15 (19.7) 57 (75.0) 4 (5.3) 
  2 49.5 37.0 - 60.5 15 (37.5) 21 (52.5) 4 (10.0) 
Isoleucine 0 48.5 ± 22.8 12 (15.8) 59 (77.6) 5 (6.6) 
  2 45 30.5 - 67.5 10 (25.0) 27 (67.5) 3 (7.5) 
Leucine 0 102.7 ± 42.1 10 (13.2) 59 (77.6) 7 (9.2) 
  2 85.5 59.5 - 118.0 5 (12.5) 33 (82.5) 2 (5.0) 
Lysine 0 155.5 115.0 - 198.5 5 (6.6) 45 (59.2) 26 (34.2) 
  2 197.5 120.0 - 253.5 0 (0.0) 22 (55.0) 18 (45.0) 
Methionine 0 11 8.0 - 17.0 35 (46.1) 37 (48.7) 4 (5.3) 
  2 14 8.5 - 20.0 14 (35.0) 25 (62.5) 1 (2.5) 
Ornithine 0 45 32.0 - 61.5 9 (11.8) 61 (80.3) 6 (7.9) 
  2 53 37.0 - 76.0 0 (0.0) 37 (92.5) 3 (7.5) 
Phenylalanine 0 73.5 62.5 - 88.0 0 (0.0) 38 (50.0) 38 (50.0) 
  2 77 63.0 - 90.0 0 (0.0) 21 (52.5) 19 (47.5) 
Proline 0 128 89.0 - 172.0 14 (18.4) 54 (71.1) 8 (10.5) 
  2 134 95.5 - 194.0 7 (17.5) 29 (72.5) 4 (10.0) 
Serine* 0 98 75.5 - 137.5 15 (19.7) 58 (76.3) 3 (3.9) 
  2 129.5 77.5 - 175.5 5 (12.5) 29 (72.5) 6 (15.0) 
Threonine 0 73 52.5 - 97.5 16 (21.1) 55 (72.4) 5 (6.6) 
  2 86.5 65.5 - 143.5 5 (12.5) 27 (67.5) 8 (20.0) 
Tryptophan* 0 29.5 23.0 - 42.0 17 (22.4) 56 (73.7) 3 (3.9) 
  2 37 ± 18.3 10 (25.0) 26 (65.0) 4 (10.0) 
Tyrosine 0 63 49.0 - 83.0 7 (22.4) 58 (76.3) 11 (14.5) 
  2 60.5 42.5 - 82.0 3 (7.5) 33 (82.5) 4 (10.0) 
Valine 0 140.7 ± 47.7 17 (22.4) 58 (76.3) 1 (1.3) 
  2 119 87.0 - 117.0 9 (22.5) 28 (70.0) 3 (7.5) 
IQR: Interquartile range; SD: Standard deviation 
*Significant differences found between day 0 and day two concentrations (alanine: p = 0.011; cysteine: p = 
0.000; serine: p = 0.027; tryptophan: p = 0.009). 
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Associations between plasma glutamine and clinical condition on admission  
Statistical analyses of the association between clinical condition and plasma glutamine were conducted 
using both day 0 plasma glutamine levels and the change in plasma glutamine that occurred between 
admission and day two.  
Plasma glutamine and diagnosis 
 
Plasma glutamine levels on admission were shown to differ significantly among diagnostic categories (p = 
0.020), as presented in Figure 8 (below). Post hoc testing revealed significant differences between medical 
and elective surgical participants (p = 0.007) and between medical and trauma participants (p = 0.013).  
 
 
Figure 8: Day 0 plasma glutamine and diagnostic category 
 
Fifty percent of trauma participants (n = 3) presented with a low plasma glutamine concentration on 
admission. Proportionately, this was followed by surgical (13.7%, n = 7), and medical (12.5%, n = 3) 
diagnoses. Conversely, 3.9% (n = 2) of surgical patients were admitted with high plasma glutamine, 
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compared to 3.7% (n = 1) of medical participants. No high plasma glutamine concentrations were found 
among participants admitted for trauma.  
 
No significant difference was found between plasma glutamine on day 0 and day two within  each individual 
diagnostic category - as seen in Table 11 (below).  
 
Table 11: Change in plasma glutamine and diagnostic category 
  Plasma Glutamine Mean ± SD (umol/l) t (df) p 
Elective Surgery Day 0 529.1 ± 163.8 0.30 
(22) 
0.766 
  Day 2 518.3 ± 194.1 




Day 2 753.3 ± 449.6 
Trauma Day 0 450.3 ± 166.7 -0.27 
(3) 
0.814 
  Day 2 500.0 ± 269.9 
Emergency Surgery Day 0 503.7 ± 165.5 -1.36 
(2) 
0.307 
  Day 2 588.0 ± 181.0 
Df: Degrees of freedom; SD: Standard deviation 
 
Plasma glutamine on admission was also not shown to differ significantly between participants admitted 
under cardiology, pulmonology, gastroenterology and other disciplines, nor did plasma glutamine change 
significantly over time from day 0 to day two between these groups (Table 12, below).  Participants with 
sepsis demonstrated the highest plasma glutamine on admission, with a mean of 736.3 ± 142.5 umol/l, as 
well as the most variation in plasma glutamine (mean 284.5 ± 399.5 umol/l) between admission and day 
two of PICU stay.  
 
Table 12: Plasma glutamine and primary diagnosis 
  Day 0 Plasma Glutamine Plasma Glutamine Change* 
  Mean (umol/l) ± SD ANOVA Mean (umol/l) ± SD ANOVA 
Cardiology 621.9 ± 204.5 
p = 0.096 
38.3 ± 188.6 
p = 0.547 
Pulmonology 516.7 ± 205.2 24.7 ± 396.4 
Gastroenterology 432.4 ± 149.2 -49.0 ± 138.5 
Sepsis 736.3 ± 142.5 284.5 ± 399.5 
Burns 492.7 ± 175.7 -16.7 ± 467.6 
Other 561.4 ± 238.5 -168.0 ± 545.6 
ANOVA: Analysis of variance; SD: Standard deviation 
*Refers to the difference in concentration between day 0 and day 2 
 
Significant differences were noted between primary diagnoses when day 0 plasma glutamine and glutamic 
acid values were combined (F(5,70) = 2.46, p = 0.041). No difference in the degree of change  of plasma 
glutamine and glutamic acid was demonstrated between groups (Table 13, below).   
 




Table 13: Plasma glutamine and glutamic acid and primary diagnosis 
  Day 0 Plasma Glutamine and Glutamic Acid Plasma Glutamine and Glutamic Acid Change* 
  Mean (umol/l) ± SD ANOVA Mean (umol/l) ± SD ANOVA 
Cardiology 724.4 ± 236.6 
p = 0.041 
-27.6 ± 202.8 
p = 0.444 
Pulmonology 609.5 ± 222.5 -8.0 ± 430.6 
Gastroenterology 506.2  ± 173.2 55.7 ± 154.6 
Sepsis 906.0 ± 196.5 18.3 ± 506.4 
Burns 528.0 ± 184.0 18.3 ± 506.4 
Other 644.0 ± 259.2 151.0 ± 516.0 
ANOVA: Analysis of variance; SD: Standard deviation 
*Refers to the difference in concentration between day 0 and day 2 
 
Significant differences in day 0 plasma glutamine and glutamic acid were found betwe en cardiology and 
gastroenterology (p = 0.018), and between sepsis and the following: pulmonology (p = 0.031), burns (p = 
0.035), gastroenterology (p = 0.006), and other (p = 0.049) - as shown in Figure 9 (below). 
 
 
Figure 9: Day 0 plasma glutamine and glutamic acid and primary diagnosis 
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Plasma glutamine and severity of disease 
As demonstrated in Figure 10 (below), Spearman’s correlation showed a trend toward a positive 
relationship between plasma glutamine on admission and the probability of death – as determined by the 
PIM 3 score. 
 
 
Figure 10: Plasma glutamine on admission and the probability of mortality 
 
The relationship between the probability of death and a combined value of day 0 plasma glutamine and 
glutamic acid reached significance (r = 0.23, p = 0.046), as demonstrated in Figure 11 (below). The 
relationship was, however, not significant when outliers were removed.  
 
 
Figure 11:  Plasma glutamine and glutamic acid on admission and the probability of mortality 
(r = 0.23, p = 0.046) 
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Plasma glutamine and infectious disease 
ANOVA testing was done to investigate associations between plasma glutamine on admission and 
participants’ infectious disease status (Table 14, below). No difference was demonstrated between plasma 
glutamine on admission among participants who were HIV exposed versus those who were not exposed (p 
= 0.340), nor between participants who were HIV positive or negative (p = 0.329). Similarly, no significant 
difference in day 0 plasma glutamine was shown between TB positive or negative participants (p = 0.627). 
The degree to which plasma glutamine changed from day 0 to day two was also not significantly different 
among any of the above groups.  
 
Table 14: Plasma glutamine and infectious disease 
    Day 0 Plasma Glutamine Plasma Glutamine Change* 
    Mean (umol/l) ± SD ANOVA Mean (umol/l) ± SD ANOVA 
HIV exposure Yes 516.9 ± 165.3 
p = 0.340 
60.7 ± 179.0 
p = 0.579 
 
No 586.4 ± 218.9 -11.8 ± 305.6 
HIV status Positive 473.3 ± 112.0 
p = 0.329 
203.5 ± 77.1 
p = 0.329 
 
Negative 581.5 ± 213.9 -3.8 ± 292.7 
TB Positive  532.0 ± 265.4 
p = 0.627 
-11.0 ± 19.8 
p = 0.931 
 
Negative 579.6 ± 207.6 7.53 ± 296.7 
ANOVA: Analysis of variance; HIV: Human Immunodeficiency Virus; TB: Tuberculosis; SD: Standard deviation 
*Refers to the difference in concentration between day 0 and day 2 
 
Plasma glutamine and routine biochemistry 
As demonstrated in Table 15 (below), Spearman’s correlation showed no significant relationships between 
day 0 plasma glutamine and any of the biochemical tests conducted on admission. A trend toward a 
positive association was, however, demonstrated between plasma glutamine on admission and platelet 
count (Spearman r = 0.22, p = 0.058). No associations were demonstrated between plasma glutamine and 
lactate, or markers of renal (urea and creatinine) and hepatic (bilirubin and liver enzymes) function. Several 
markers of infection – including CRP, PCT, and white cell count – were negatively correlated to plasma 
glutamine on admission, although none of these relationships were significant.  
 
Mann Whitney U tests were conducted to compare plasma glutamine between patients with raised, and 
those with normal, markers of infection on admission. No significant differences were found between 
participants with elevated CRP (p = 0.097, n = 17) or PCT (p = 0.621, n = 14), when compared with those 
with normal infectious parameters. The plasma glutamine concentration of participants with obviously low 
albumin (≤20 g/l) at admission was also not significantly different to those with normal albumin levels (p = 
0.631, n = 28). Similarly, no difference was demonstrated between groups when the sum of glutamine and 
glutamic acid was used.  
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Table 15: Day 0 plasma glutamine and biochemistry 
  n Spearman r p 
Lactate (mmol/l) 73 0.04 0.759 
Glucose (mmol/l) 73 0.00 0.997 
Urea (mmol/l) 76 0.01 0.963 
Creatinine (umol/l) 75 0.03 0.815 
CRP (mg/l) 17 -0.18 0.497 
PCT (ug/l) 14 -0.25 0.391 
Albumin (g/l) 28 0.26 0.180 
Bilirubin (umol/l) 16 0.31 0.247 
Conjugated bilirubin (umol/l) 16 0.36 0.166 
ALT (U/l) 16 0.01 0.965 
AST (U/l) 16 0.01 0.974 
ALP (U/l) 12 0.38 0.217 
GGT (U/l) 10 0.41 0.238 
Haemoglobin (g/dl) 73 -0.12 0.313 
White cell count (x109) 73 -0.05 0.670 
Platelets (x 109) 73 0.22 0.058 
ALT: Alanine Transferase; AST: Aspartate Aminotransferase; CRP: C- Reactive 
Protein; GGT: Gamma-Glutamyl Transferase; PCT: Procalcitonin 
 
Associations between plasma glutamine and nutritional status  
Statistical analyses of the association between nutritional status and plasma glutamine were conducted 
using both day 0 plasma glutamine levels and the change that occurred in glutamine concentration 
between days 0 and two.  
 
ANOVA testing did not reveal any significant differences in day 0 plasma glutamine between any of the 
anthropometrical categories (Table 16, below). In addition, no notable difference was shown in the degree 
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Table 16: Plasma glutamine and nutritional status 
  Day 0 Plasma Glutamine Plasma Glutamine Change* 
  Mean (umol/l) ± SD ANOVA Mean (umol/l) ± SD ANOVA 
Weight-for-age 
    Normal 554.9 ± 236.0 
p = 0.895 
20.4 ± 286.7 
p = 0.532 Moderately underweight 546.9 ± 131.4 -158 ± 517.5 






Normal 558.8 ± 188.3 
p = 0.500 
62.4 ± 249.2 
p = 0.817 Moderate stunting 638.9 ± 339.9 0.3 ± 264.6 
Severe stunting 522.0 ± 54.8 -3.8 ± 176.4 





Normal 562.1 ± 219.1 
p = 0.866 
58.3 ± 256.9 
p = 0.523 
Moderate wasting 609.6 ± 225.2 35.0 ± 210.0 
Severe wasting 529.0 ± 92.2 -51.2 ± 183.5 
Obese 547.5 ± 31.8 332.0± - 
Weight-for-height +MUAC         
Normal 565.9 ± 224.2 
p = 1.00 
58.3 ± 256.9 
p = 0.523 
Moderate wasting 560.3 ± 201.0 35 ± 183.5 
Severe wasting 569.7 ± 145.4 -51.2 ± 183.5 
Obese 547.5 ± 31.8 332.0± - 
ANOVA: Analysis of variance; BMI: Body Mass Index; MUAC: Mid Upper Arm Circumference; SD: Standard 
deviation    
*Refers to the difference in concentration between day 0 and day 2     
 
A significant inverse relationship was demonstrated between day 0 plasma glutamine and participant 
weight (Spearman r = -0.24, p = 0.046, n = 72) - as seen in Figure 12 (below). Significant inverse 
relationships were also shown between plasma glutamine on admission and participant length/height 
(Spearman r = -0.26, p = 0.035, n = 64), and MUAC (Spearman r = -0.27, p = 0.044, n = 57).  
 
 
Figure 12: Plasma glutamine on admission and participant weight  
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No significant relationship was found between plasma glutamine on admission and weight-for-height/BMI, 
nor between the degree of change in plasma glutamine over time and any of the above anthropometrical 
parameters.  
Associations between plasma glutamine and nutritional intake 
Associations between nutritional intake during the first two days of PICU stay and d ay two plasma 
glutamine were investigated using Spearman’s correlation. No significant  associations were demonstrated - 
as indicated in Table 17 (below). Similarly, no significant associations were found between nutritional 
intake and the degree to which plasma glutamine changed over the first 48 hours of PICU stay. 
 
Table 17: Day two plasma glutamine and nutritional intake 
  n Spearman r P 
Average energy (kcal/day) 38 -0.14 0.413 
Average protein (g/day) 38 -0.15 0.367 
Energy requirements met (%) 36 -0.12 0.488 
Protein requirements met (%) 36 -0.20 0.248 
 
ANOVA testing was conducted to identify differences in day two plasma glutamine among participants who 
had met 66% of energy requirements and those who had not. No significant difference was noted (p = 
0.730). Although plasma glutamine increased more from day 0 to day two among participants who met 
66% of requirements (mean 107 ± 137.3 umol/l) compared to those who did not (mean 20.8 ± 239.2 
umol/l), this difference was not significant (p = 0.550).  
Associations between plasma glutamine and clinical outcome 
Spearman’s correlations were run to investigate associations between clinical outcome and plasma 
glutamine on day 0 and day two of PICU stay, as well as the change that occurred over this time (Table  18, 
below). No significant associations were demonstrated between plasma glutamine and the length of time 
spent on mechanical ventilation or PICU LOS. A positive relationship was, however, found between day 0 
plasma glutamine and hospital LOS (Spearman r = 0.26, p = 0.032), indicating that higher plasma glutamine 
on admission is associated with longer time spent in hospital (Figure 13, below). Outlier sweeps were 
conducted for each of the clinical outcome parameters, the results of which are indicated, in parentheses, 
in Table 18. With outliers excluded, a significant relationship was not demonstrated between plasma 
glutamine on admission and hospital LOS. However, a trend toward a positive association was shown 
(Spearman r = 0.23, p = 0.067).  
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Table 18: Plasma glutamine and clinical outcome 
  n Spearman r p 
Mechanical ventilation (hr) 
   Day 0 Glutamine 75 (70) 0.14 (0.13) 0.227 (0.303) 
Day 2 Glutamine 40 (35) -0.13 (-0.10) 0.420 (0.552) 
Change in Glutamine* 40 (35) 0.18 (0.10) 0.272 (0.570) 
PICU LOS (hr) 
   Day 0 Glutamine 69 (64) 0.07 (0.081) 0.558 (0.523) 
Day 2 Glutamine 36 (32) -0.28 (-0.19) 0.097 (0.285) 
Change in Glutamine 36 (32) 0.29 (0.30) 0.088 (0.100) 
Hospital LOS (days) 
   Day 0 Glutamine 68 (65) 0.26 (0.23) 0.031 (0.067) 
Day 2 Glutamine 35 (33) -0.13 (-0.14) 0.446 (0.440) 
Change in Glutamine 35 (33) 0.31 (0.31) 0.074 (0.079) 
LOS: Length of stay 
Results following the removal of statistical outliers are presented in parentheses  




Figure 13: Day 0 plasma glutamine and hospital length of stay 
 
Interestingly, the change that occurred between plasma glutamine and glutamic acid (combined) from 
admission to day two was negatively correlated with hospital LOS (Spearman r = -0.34, p = 0.046, n = 35) – 
as demonstrated in Figure 14 (below). This result was further confirmed when outliers were excluded 
(Spearman r = -0.36, p = 0.043, n = 33).  
r = 0.26, p = 0.032 




Figure 14: Plasma glutamine and glutamic acid change and hospital length of stay 
 
ANOVA testing was done to further investigate the relationship between plasma glutamine on admission 
and the length of hospital stay. Plasma glutamine was categorised as low (<420 umol/l), normal (420-930 
umol/l), and high (>930 umol/l), and the means were compared between groups. No significant difference 
in hospital LOS was noted between groups. 
 
ANOVA was used to compare plasma glutamine among participants requiring ventilation with those who 
did not. No significant differences were found in day 0 or in day two plasma glutamine between groups. 
Participants requiring ventilation demonstrated a slight reduction in plasma glutamine over the first 48 
hours of PICU stay (mean -1.36 ± 302.6 umol/l), whereas those who were not ventilated showed an 
increase in plasma glutamine over this time (mean 78.25 ± 101.2 umol/l). This difference was not, however, 
significant (p = 0.610).  
 
Differences in plasma glutamine were also investigated among participants who died versus those who 
survived. No significant difference was noted in plasma glutamine on admission between participants who 
died, compared to those who survived (p = 0.158). Higher plasma glutamine on day two (mean 812.4 ± 
583.2 umol/l, n = 5) was demonstrated in participants who died, when compared to survi ving participants 
(mean 547.3 ± 222.1 umol/l, n = 35), a difference which approached significance (p = 0.057) .  
 
Plasma glutamine was shown to increase from day 0 to day two among participants who survived (mean 
26.4 ±236.9 umol/l, n = 35) and to reduce among those who died (mean -132.2 ± 556.7 umol/l, n = 5). 
Again, this was not a significant result (p = 0.256). From the data, it did appear as if there was greater 
Spearman r = -0.34, p = 0.046 
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variability in plasma glutamine on day 0 and day two, and a greater margin of change during this time 
among those who died. 





It is clear that before large-scale interventions are conducted, a more thorough understanding of plasma 
glutamine concentration among specific patient subgroups is needed.18 One group for whom data is lacking 
is children - particularly the critically ill.20 This exploratory study investigated the plasma glutamine status of 
critically ill children on admission, and during the first two days of PICU stay. Furthermore, associations 
between plasma glutamine and clinical condition on admission, nutritional status, nutritional intake, and 
clinical outcome were explored. Data were collected from consecutive patients admitted to the RCWMCH 
PICU over a one-month period, making the sample largely representative of the unit’s typical patient 
profile.  
 
The study found that plasma glutamine concentrations on admission to and on day two of PICU stay were, 
for the majority of participants, normal. No notable change in plasma glutamine status took place over this 
period. Significant differences existed in plasma glutamine between diagnostic groups . However, no 
associations were demonstrated with regard to other markers of clinical condition on admission.  Both 
nutritional status and intake appeared to be largely unrelated to plasma glutamine, as were most markers 
of clinical outcome. A positive trend was, however, demonstrated between plasma glutamine on admission 
and hospital LOS. In addition, significantly more change in plasma glutamine and glutamic acid occurred 
over the first two days in PICU in those who spent less time in hospital. Although no link was made 
between plasma glutamine and mortality, higher plasma glutamine was demonstrated on day two of PICU 
stay among those who died - a result which approached significance.    
 
When comparing these results to the available literature, a distinction must be made between 
observational studies (as detailed in Tables 1 and 2 in the literature review) and interventions in which 
glutamine was administered as a supplement - the latter of which are not directly comparable to the 
current study.  
Plasma glutamine during the first two days of PICU stay 
Plasma glutamine on admission to PICU 
In their work with children diagnosed with meningococcal disease, Marino et al. demonstrated low plasma 
glutamine on admission to the PICU and concluded that, as with many adults, paediatric patients 
experience plasma glutamine depletion during the acute phase of critical illness. 21 This was in direct 
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contrast to this study, which observed mostly normal plasma glutamine concentrations on admission to 
PICU.  
 
Other studies have also shown normal plasma glutamine concentrations among critically ill patients on 
admission, but reported a higher prevalence of glutamine depletion compared to this study.22,24,59,60 Ekmark 
and colleagues reported mean plasma glutamine concentrations comparable to this study, but found that 
40% of patients within their paediatric cohort were glutamine deplete. 22 This is markedly higher than the 
17.1% of participants presenting with low plasma glutamine in this study. In adult literature , the reported 
prevalence of glutamine depletion has varied among mixed and specific subgroups of critically ill 
patents.24,58–60,66 Both Oudemans-van Straaten et al.24 and Nienaber and colleagues58 reported normal 
plasma glutamine on presentation to the ICU (at similar concentrations to this study) - but identified 
depletion among 31% and 38% of patients respectively. Higher proportions of up to 65% of patients with 
glutamine depletion have been noted by others.60 Thus, there is no clear picture regarding the prevalence 
of glutamine depletion among critically ill children or adults. This study diverges from what has been 
demonstrated in the paediatric and adult literature, by showing normal plasma glutamine concentrations 
and proportionately fewer patients with glutamine depletion on admission to PICU.   
 
Healthy controls have been used in some studies for comparative purposes. Both Ekmark et al.22 and 
Marino and colleagues21 reported significantly lower plasma glutamine concentrations among critically ill 
children when compared to healthy subjects. This distinction in plasma glutamine concentrations between 
healthy and critically ill individuals has also been shown in the literature on adults.65 The current study did 
not, however, include a control group. In addition, data on normal plasma glutamine concentration among 
healthy South African children does not exist, making it difficult to contextualise these results.   
 
Despite a well-established link between mortality and plasma glutamine concentrations >930 umol/l,59 very 
few studies have reported on the prevalence of plasma glutamine above this cut off.  In the controversial 
REDOXS study, 15% of the small subset of patients for whom glutamine concentration was measured had 
raised plasma levels, which arguably was sufficient reason to avoid the high dose blanket supplementation 
to follow.13 Closer to home in South Africa, Nienaber and colleagues found that 7% of critically ill adult 
patients had elevated glutamine concentrations on admission to ICU.58 Similarly, this study found that 5% 
of participants had plasma concentrations >930 umol/l.  
Plasma glutamine on day two of PICU stay 
This study showed that, on average, plasma glutamine concentrations on day two of PICU stay remained 
normal. Although not statistically significant, the percentage of patients with low plasma glutamine 
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increased from admission (17%) to day two (27%) of PICU stay - suggesting that plasma glutamine status 
worsened fractionally during this period.   
 
Exploratory research among critically ill paediatric patients has demonstrated some improvement in 
glutamine status over time; however, the time-frames used to obtain repeat plasma samples were vastly 
different between studies.21,22 Marino and colleagues reported plasma glutamine on admission and again 
during convalescence (a measure which took place, on average, 55 days post PICU discharge), and found an 
improvement in mean plasma glutamine from 52% to 26% below the normal range respectively. 21 In their 
study, Ekmark et al. found that plasma glutamine concentrations among a mixed cohort of critically ill 
children had normalised by day five of PICU stay, without exogenous supplementation.22 Similarly, slow 
improvement in plasma glutamine was demonstrated from admission to day six of ICU stay among adult 
trauma patients.66 All three of these studies could not, however, describe the changes that occurred in 
plasma glutamine during the acute phase of critical illness.   
 
The work done in 2008 by Villares et al. among children with congenital heart disease is perhaps more 
comparable to the current study, in that plasma glutamine was measured early on in the post-operative 
period on day one, three, and then later on day seven. Although slow correction was seen in the 
concentrations of all amino acids over time, glutamine recovery was the most delayed - remaining 
significantly lower than pre-operative concentrations seven days after surgery.116 This delayed recovery by 
up to one week is in contrast to other paediatric findings, but corroborates what had previously been found 
in adult patients following major surgery.64  
 
In the current study, participants presenting to the PICU with glutamine depletion were more likely to have 
reduced concentrations 48 hours later - an association that lost statistical significance after the removal of 
outliers. In addition, the prevalence of low plasma glutamine increased (not significantly) from admission to 
day two of PICU stay. This could infer that in these patients, plasma glutamine correction had not yet 
occurred during the first 48 hours of PICU stay.   
 
In their observations of critically ill adults, Buter and colleagues measured plasma glutamine concentrations 
daily throughout the course of ICU stay. It is unfortunate that a detailed description of the changes that 
occurred in plasma glutamine over time was not included in their final report. 60 This would have provided 
useful information about the glutamine response during and beyond the acute phase of critical illness.   
 
The purpose of observational research is to increase knowledge in a particular field, and to inform future 
interventions. The results of this study have challenged the notion that critically ill children are glutamine 
deplete during the acute phase of illness – and do not support blanket supplementation with the nutrient. 
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Reasons for the discrepancy between this study and others (within paediatric critical care), and the 
differences in the reported prevalence of glutamine depletion, need to be considered.  
Reference ranges 
It must be noted that the reference ranges used for plasma glutamine vary between studies. In 1992, 
Laposta established the lower limit of plasma glutamine at 420 umol/l.137 Based on mortality outcomes in 
critically ill adults, both Oudemans-van Straaten24 and Rodas and colleagues59 confirmed this cut off and 
dichotomised their data accordingly. Ekmark et al. corroborated this in paediatrics, by reporting that 420 
umol/l was -2SD below that of healthy controls and could therefore be considered low.22 The group 
subsequently established a link between low plasma glutamine  and increased morbidity. Thus mortality 
data in adults and morbidity data in children have confirmed this lower limit.18 
 
Less is known about what constitutes high levels of plasma glutamine. Concentrations of ≥930 umol/l in 
adult patients have been associated with increased mortality. However, this result was based on only a few 
patients demonstrating high glutamine concentrations.59 Ekmark and colleagues suggested an upper limit 
of 760 umol/l; a value +2SD higher than that seen in healthy controls.22 Paediatric age-specific reference 
ranges for plasma glutamine have also been described by Blau et al. - ranges that were used by the 
laboratory employed in this study.127  
 
The study by Marino and colleagues was unique in that a combined value for glutamine and glutamic acid 
was calculated, in order to account for the spontaneous conversion of glutamine to g lutamic acid during 
processing. A reference range of >600 umol/l was used to denote normal levels - a cut off that has not been 
described elsewhere.21 Oudemans-van Straaten et al. acknowledged this loss of plasma glutamine to 
glutamate by analysing both, and found a 6.5% loss of glutamine to glutamic acid. As such, the authors 
chose to analyse their data using the combined value of plasma glutamine and glutamic acid.24 It is clear 
that there are differences in reference ranges and in the measurement of plasma glutamine among 
available observational studies, making comparison difficult and firm conclusions nearly impossible to 
draw.  
 
For the purposes of this study, plasma glutamine was investigated independently as well as in combinat ion 
with plasma glutamic acid. This was done to allow for comparison between studies and to exclude the 
possibility of falsely low plasma glutamine concentrations. In addition, plasma glutamine concentration was 
analysed using reference ranges established by clinical outcome data24,59 as well as the paediatric ranges 
specified by Blau et al.127 In both cases, low proportions of patients were shown to be glutamine deplete on 
admission to PICU; numbers which elevated slightly but non- significantly by day two.   




Differences between the reference ranges were more apparent when looking at participants with high 
plasma glutamine. According to the reference ranges of Blau et al.,127 15.8% of patients had elevated 
plasma glutamine on admission, which increased to 20% by day two. This contrasts with the 5.3% and 5% of 
participants shown to have raised plasma concentrations on admission and day two when using the more 
popular reference range. These disparities raise questions over which reference range s should be used in 
paediatrics, and how this choice may have influenced the results of existing studies.  
Plasma glutamine: a proxy for whole body glutamine? 
Increased consumption of glutamine during critical illness is thought to precipitate tremendous f lux of the 
amino acid between organs. It is unclear to what extent plasma glutamine levels represent th is 
mobilisation.24 As a result, there is controversy over the use of plasma concentration as a proxy for whole 
body glutamine during periods of metabolic stress. Questions have been asked about whether we are 
measuring glutamine status correctly. What is also unknown at this point is if, at certain stages of critical 
illness, plasma glutamine concentration reflects whole body glutamine better than others. This would have 
a major bearing on how existing studies are interpreted and compared.  
 
A reduction of up to 72% in skeletal muscle glutamine concentration has been reported among  several 
critically ill adult populations.61,62,65,138,139 As a result, glutamine concentration in skeletal muscle has been 
studied as a means to evaluate whole body glutamine during critical illness.24 This was, however, 
challenged in 2004 by Tjader and colleagues who demonstrated that muscle glutamine concentrations 
remained persistently low in patients with MOF - despite escalating doses of intravenous supplementation. 
The group hypothesised that low concentration of glutamine in the muscle may reflect a general state of 
inflammation rather than whole body depletion.140 Soeters et al. also suggested that tissue glutamine 
concentrations be interpreted with caution, as alterations in membrane integrity and transport systems 
could mean that the steep uphill gradient between plasma and tissue cannot be maintained.26 Questions, 
therefore, still remain over the use of skeletal muscle concentration as a proxy for glutamine status during 
critical illness.  
 
Plasma glutamine response to critical illness is thought to be less distinct than that of skeletal muscle, and 
may vary over time.24 As Oudemans-van Straaten and colleagues pointed out - the release of glutamine 
from muscle tissue may initially increase or maintain plasma glutamine concentration. As such, normal 
plasma glutamine concentrations may not exclude whole body glutamine depletion; however, low plasma 
glutamine is likely to reflect depletion. Low plasma glutamine would therefore be considered a relevant 
marker of whole body glutamine depletion.24 In contrast, others postulate that low plasma glutamine may 
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not be due to an overall shortage, but due to fluid shifts that occur during metabolic stress. According to 
this theory, increases in intravascular and extravascular spaces during critical illness may have a dilutional 
effect on amino acids in the plasma.26 
 
Despite this uncertainty, the finding that low plasma glutamine is an independent risk factor for increased 
mortality among adult patients,24,59 and is linked to MOF among critically ill children,22 indicates that plasma 
glutamine is a useful clinical biomarker. Furthermore, plasma glutamine is currently the most cost-
effective, accessible, and least invasive proxy. What would be useful is consensus about the reference 
ranges used and the measurement of plasma glutamine independently or in conjunction with glutamic acid.  
This would allow for comparison between studies, which would add to the limited knowledge base in this 
field in a significant way.  
Clinical condition on admission 
Diagnostic profile  
Worldwide, PICUs are home to a heterogeneous mix of conditions, ranging from acute or chronic illness, to 
post-operative care, injury, and others.141 The diagnostic profile of the current cohort was heavily weighted 
by elective surgical - in particular, post-operative cardiac patients, who comprised just less than half of the 
total participants.  
 
Solomon and colleagues conducted a retrospective audit of patients admitted to the PICU of RCWMCH 
between the years 2000 and 2006. A notable difference between studies in RCWMCH was the rise in post-
operative cardiac patients over time - with 11.8% of bed spaces occupied by this subgroup in 2000, 17.8% 
in 2006, and 47% over a one-month period in 2016.117 The current cohort appears to represent the 
changing diagnostic profiles seen within the unit. 
 Plasma glutamine and diagnostic profile 
Observational studies on plasma glutamine in paediatrics have differed in terms of the diagnostic profile of 
participants. Marino et al. focused solely on patients with severe meningococcal disease - a diagnosis 
frequently associated with sepsis and MOF.21 On the other hand, Ekmark and colleagues included a more 
diverse PICU population of surgical and medical patients; a cohort that included neurosurgical and thoracic, 
but excluded cardiac surgery patients.22 Similarly, in their work with critically ill adults, Oudemans-van 
Straaten et al. included seriously ill patients admitted non-electively to ICU, thus excluding cardiac and 
other elective surgical patients.24 Rodas et al. also excluded thoracic, neurosurgical, and trauma patients.59 
In contrast to these studies, post-operative cardiac patients comprised a large proportion of the current 
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cohort. Given such variation between studies, consideration must be given to diagnostic profile as a 
potential reason for the differences in reported prevalence of plasma glutamine depletion duri ng critical 
illness. 
 
The question must also be asked if the inclusion of so many post-operative cardiac patients may have 
inclined this study to show more favourable glutamine concentrations compared to others. Thi s is 
particularly relevant as plasma glutamine concentrations among cardiac patients in this study were shown 
to be normal in the immediate post-operative period, and on day two of PICU stay. This finding is not, 
however, corroborated by other literature - further insulating this study from others. Plasma glutamine 
concentrations of paediatric post-operative cardiac patients have been shown to decrease significantly 
following surgery (on day one, two, and three),115,116 and to remain low for up to one week.116  
 
Plasma glutamine concentrations between different diagnostic groups were compared in order to ascertain 
if any one group in particular influenced the results of this study. Significant differences were demonstrated 
in combined concentrations of plasma glutamine and glutamic acid between cardiology and 
gastroenterology diagnoses, and between sepsis and pulmonology, burns, gastroenterology, and ‘other’. 
This suggests that from a diagnostic perspective, sepsis, more than cardiology, stood out. Only 5% of 
participants in this study presented to the PICU with a primary diagnosis of sepsis, making firm conclusions 
difficult to draw. This subgroup of septic patients was, however, shown to have the highest plasma 
glutamine and combined values of glutamine and glutamic acid, as well as the widest range of 
concentrations.  
 
The relationship between plasma glutamine and sepsis has been investigated before, with rather 
interesting results. In their work with adults, Oudemans-van Straaten and colleagues identified septic shock 
as the primary diagnosis most frequently related to low plasma glutamine.24 Reduced concentrations of 
glutamine have also been described among other populations of septic adult patients.58,142,143 In paediatrics, 
little is known about plasma glutamine during sepsis. In their study on infants and children with meningitis, 
a diagnosis frequently associated with sepsis, Marino et al. reported low plasma glutamine during the acute 
phase of illness.21 This is in sharp contrast to the findings of this study. 
 
Alterations in glutamine metabolism have also been identified during sepsis. In 2013, Kao and colleagues 
described increased hepatic clearance of glutamine and reduced uptake by enterocytes among septic 
patients.142 In sepsis, therefore, it appears as though immune cells and the liver are the primary consumers 
of glutamine - compared to non-septic patients whose immune and gastrointestinal systems utilise most 
glutamine during critical illness.143   
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Glutamine supplementation has been increasingly discouraged among septic patients on the back of the 
‘inflammation hypothesis’.143 In situations of increased glutamine consumption, proteolysis of skeletal 
muscle occurs in order to provide the glutamine required. 26 As a major fuel source for immune cells, 
glutamine consumption increases once lymphocytes are activated. It has been suggested that the release of 
interleukin 1 (Il-1) and interleukin 2 (Il-2) from lymphocytes and macrophages depends on plasma 
glutamine concentration.144,145 Instead of enhancing immune function, large infusions of glutamine given to 
patients with sepsis or organ failure could, in fact, prompt an exaggerated inflammatory response which 
may have a negative impact on outcome.143 This hypothesis could explain the contradicting results between 
studies, which have been conducted on patients with varying degrees of inf lammation and sepsis.13,15,79   
 
Interestingly, 68% of patients enrolled in the REDOXS study had septic shock. In their dose finding study 
prior to the intervention, plasma glutamine was normal among most of the 66 patients included.13 
Although no information was provided regarding the diagnostic profile of this subgroup of patients , it 
would have been interesting to see what proportion was septic.   
 
It appears as if both plasma glutamine concentration and the role of exogenous glutamine during sepsis are 
areas that require more scrutiny. Increased mortality has been demonstrated among patients with sepsis 
who received glutamine supplementation.13 As such, an in-depth understanding of plasma glutamine 
concentration in this group is now clearly required. Although the numbers of septic participants in the  
current study were low, the finding that plasma glutamine was highest among this group contradicts what 
has been demonstrated in adult patients thus far. The question now is whether this suggests a different 
glutamine response to sepsis in paediatrics, or whether this was unique to the mixed cohort included in this 
study.  
 
Aside from primary diagnoses, this study also showed differences in plasma glutami ne across diagnostic 
categories - with concentrations on admission differing significantly between medi cal and trauma, and 
between medical and elective surgical patients. Trauma patients presented with proportionately more 
glutamine depletion on admission, followed by surgical and then by medical patients. In their intervention, 
Perez-Barcena et al. reported glutamine depletion among 60% of trauma cases on presentation to the 
ICU.66 This, in some way, supports the finding of this study with regard to trauma. However, these results 
are in contrast to what has been found in mixed cohorts of critically ill adults. In their study of ICU patients, 
Oudemans-van Straaten and colleagues reported a normal to high plasma glutamine among patients 
admitted with trauma, and showed that 37% and 21% of medical and surgical patients  had low plasma 
glutamine on admission to ICU respectively.24 This suggests that proportionately more medical patients 
experience glutamine depletion when compared to surgical patients. Along similar lines, Buter et al. 
reported significantly lower plasma glutamine concentrations among non-elective (medical, trauma and 
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emergency surgery), when compared to elective (primarily surgical) patients on presentation to the ICU.60 
This was further confirmed in 2016 by Nienaber and colleagues, who showed lower plasma glutamine 
among medical versus surgical patients on admission to the ICU.58  
 
Potential reasons for these findings have been put forward. Buter et al. suggested that increased infection 
in non-elective, when compared to post-operative elective surgical patients, may have played a role. In 
addition, non-elective patients generally experience an extended period of time from the onset of illness to 
ICU admission. The authors suggested that metabolic stress over a longer period may have resulted in more 
glutamine depletion among this group of patients.60 Of course, this rationale cannot explain the results of 
the current study.  
 
In several studies on plasma glutamine concentration among mixed critically ill populations, patients were 
not stratified according to diagnosis, but rather by severity of disease and clinical outcome.22,59 
Observational studies of specific diagnostic groups such as those with meningococcal disease and post-
operative cardiac surgery, have proven valuable in describing low plasma glutamine among particular 
patients. Additional data on the diagnostic profile of patients would be a useful addition to future studies , 
in order to identify which, if any, patients are consistently glutamine deplete.  
 
The current study has highlighted the importance of diagnosis when studying plasma glutamine in critically 
ill children. Sepsis, in particular, emerged as a diagnosis that requires further investigation with regard to 
plasma glutamine. In addition, the study’s novel findings with regard to diagnostic groups certainly warrant 
closer scrutiny. 
Severity of illness and mortality risk 
In this study, a positive correlation was shown between the combined concentrations of plasma glutamine 
and glutamic acid on admission and the probability of mortality. Similarly, participants with higher plasma 
glutamine (independent of glutamic acid) on admission tended to be at increased risk of death. Both 
associations were, however, weak and significance was lost once outliers were removed. These results are 
not definitive, but provide some suggestion of a potential relationship between plasma glutamine and 
mortality risk.  
 
The relationship between plasma glutamine, severity of disease, and mortality risk has been studied among 
critically ill adult cohorts. Only one study to date has established a link between plasma glutamine and 
severity of disease.60 However, most have shown low plasma glutamine concentration on admission to ICU 
as being independent of disease severity and mortality risk profiling.146 Rodas et al. found no significant 
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difference in APACHE II (Acute Physiology and Chronic Health Evaluation) scores between patients with 
plasma glutamine concentrations of <420 umol/l when compared to those with normal glutamine status.59 
In their study, Oudemans-van Straaten and colleagues used four scoring systems to assess severity of illness 
and predicted mortality. Although a trend was noted toward lower plasma glutamine being associated with 
higher severity of illness and mortality predictions, no significant link was found between plasma glutamine 
and patient risk scoring.24 From these results, it appears as if low plasma glutamine is not always a 
characteristic of the sickest of patients in an ICU setting.146 This concept among adult populations is an 
important one, and one which was largely ignored by Heyland et al. when recruiting septic patients with 
MOF into the REDOXS study.13 The results to follow could perhaps have been avoided, had glutamine 
depletion not been presumed among the sickest of ICU patients.  
 
Because of the paucity of data on plasma glutamine levels in critically ill children, little is known about the 
relationship between severity of disease scoring and plasma glutamine. Both PRISM (Paediatric Risk of 
Mortality) and PIM 2 scores were used by Marino et al. to predict mortality - neither of which were 
associated with plasma glutamine concentration. The authors mentioned however, that glutamine status 
was in some way  associated with disease severity, in that significant inverse relationships were shown 
between plasma glutamine and PICU LOS, duration of mechanical ventilation and the biochemical 
measures lactate, and CRP.21 This could highlight a difference in the relationship between plasma glutamine 
and severity of disease, as determined using a scoring tool versus clinical presentation and outcome.  
 
In addition to the lack of data in paediatric patients, comparison between existing studies is made difficult 
by the use of different scoring tools. In saying that, neither the available data from adult nor paediatric 
cohorts support the finding of this study - which suggests that the higher the plasma glutamine on 
admission, the higher the risk of mortality.  
 
This result could theoretically coincide with the U-shaped curve discussed by Rodas and colleagues, in 
which both low and high plasma glutamine concentrations were associated with increased mortality.59 It 
must be noted that predicted and actual mortality are not directly comparable. Because of the limited 
sample size of this study, demonstrating an association between actual mortality and plasma glutamine 
was unlikely to occur. Despite this - could a positive association (albeit a weak trend) between plasma 
glutamine and mortality risk scoring suggest that as in adults, elevated plasma glutamine places children at 
risk of potential harm? This question certainly warrants further study.  
 
Another question more specific to this study, is whether statistical outliers should have been excluded from 
the data analysis. It could be argued that in a setting where data were collected from live subjects, both 
high and low plasma glutamine concentrations could have been clinically relevant and should not have 
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been disregarded. Inclusion of statistical outliers would have strengthened the argument put forward by 
this study that higher plasma glutamine and glutamic acid on admission to PICU is associated with an 
increased risk of mortality.  
Infectious disease status 
Like many low-resourced countries, South Africa faces a significant burden of infectious disease. At 12.6% 
of the population and 19% of the global estimate, the country is thought to have the highest prevalence of 
HIV in the world in adults over the age of 15 years.118,147 Although the epidemic remains at record levels, 
new infections are gradually declining.147 Almost 30% of South Africans are below the age of 15 years. An 
estimated 280 000 children aged 0-14 years were living with HIV in 2017, equating to 1.7% of the 
population within this age bracket.118 In this study, 3.9% of participants were infected with HIV - more than 
double the national prevalence.  
 
TB is another major challenge within the South African health sector, and is thought to be closely related to 
HIV.148 An estimated 0.8% of the population suffer from active disease every year, 13% of which are  
children.119 Six percent of participants included in this study tested positive for TB, a figure which is 
significantly higher than the domestic estimate. 
 
In light of the above context, it made sense for this study to explore potential associations between plasma 
glutamine and infectious disease. In their early work on protein metabolism in conditions associated  with 
cachexia, Hack et al. suggested that HIV infection was associated with low plasma glutamine concentration 
- likely the result of concomitant infections and increased burden on the immune system.149 More recently, 
this was challenged by Nienaber and colleagues who reported normal plasma glutamine concentrations 
among HIV-positive adults on admission to two South African ICUs. The group demonstrated comparable 
inflammatory markers between HIV-positive and HIV-negative patients, and argued that less pronounced 
inflammation in HIV-infected patients than expected, could account for normal plasma glutamine 
concentrations in this group.58  
 
Most studies on plasma glutamine status do not mention infectious disease - likely because the disease 
burden is far lighter elsewhere. However, the therapeutic role of glutamine supplementation in infectious 
disease has, to some degree, been considered. People living with HIV who received exogenous glutamine 
demonstrated reduced duration and severity of diarrhoea associated with both infection150 and 
antiretroviral (ARV) therapy.151 In addition, glutamine has been studied as a potential means to reduce the 
oxidative burden of HIV. Supplementation of the amino acid to HIV-infected patients was shown to 
increase glutathione levels, but has not yet been shown to directly impact antioxidant capacity.152  




This study is, to our knowledge, the first to investigate associations between plasma glutamine and 
infectious disease status among critically ill children - in the absence of glutamine supplementation. No 
significant differences were found in plasma glutamine among those infected with HIV or TB and those who 
were not, implying that infectious disease has no bearing on glutamine status. Because the numbers of 
participants with infectious disease were low, these results must however be interpreted with caution. 
Despite this, the findings of this study enhance knowledge in an area in which research is lacking. In the 
case of HIV infection, and perhaps in the context of a larger study, it would have been interesting to explore 
the relationship between ARV use and plasma glutamine, as this association has not yet been investigated 
elsewhere.  
Biochemistry 
Biochemical indicators of clinical condition, including markers of infection, albumin, lactate, and measures 
of hepatic and renal function, have been investigated in relation to plasma glutamine concentration.21,143 
This study found no significant associations between plasma glutamine and any biochemical measure, 
which is surprising given what the literature has demonstrated thus far. Albumin was one of two 
biochemical indices measured by Oudemans-van Straaten and colleagues, and was reported to be 
significantly lower in patients who were glutamine deplete compared to those with normal plasma 
concentrations.24 A positive association between plasma glutamine and albumin was recently confirmed in 
2015 by Pan et al., in their work with adult colorectal cancer patients.153 In the paediatric cohort of Marino 
et al., albumin was reported to be normal on admission to PICU, and no association with plasma glutamine 
was found.21 Combined with the results of this study, it appears as if the relationship between plasma 
glutamine and albumin that has been demonstrated in adults, has not yet been confirmed in children.  
 
Marino and colleagues did, however, describe inverse relationships between plasma glutamine and lactate, 
as well as CRP, but found no relationship with Il -6, Il-10, and tumour necrosis factor (TNF) ἀ.21 Inverse 
associations between plasma glutamine and markers of infection and inflammation (particu larly Il-664 and 
CRP154) have been well established in adult literature. This was recently confirmed in a mixed cohort of 
critically ill adult patients by Neinaber et al., who demonstrated an inverse relationship between plasma 
glutamine and CRP, and a trend toward the same with the inflammatory marker Il-6.58 Interestingly in the 
current study, PCT, CRP, and white cell count were inversely correlated to plasma glutamine  - but not 
significantly so.  The direction of these correlations is in keeping with existing literature, and could reflect 
raised glutamine utilisation by immune cells during periods of physiological stress. In this study, however, 
plasma glutamine concentrations were comparable among participants with normal and high markers of 
infection.  
Stellenbosch University  https://scholar.sun.ac.za
82 
 
Although not consistently the case, elevated plasma glutamine concentrations have been identified in adult 
patients with liver failure71 and chronic renal dysfunction.73 Raised plasma glutamine concentrations were 
also recently demonstrated by Fadel et al. in children with chronic kidney disease , when compared to 
healthy controls.72 No associations between plasma glutamine and urea, creatinine, or any of the liver 
enzymes, were demonstrated in this study. In the study by Marino et al., 81% of the paediatric patients 
included required renal support. However, no association was demonstrated between plasma glutamine 
and urea or creatinine.21 Although Ekmark and colleagues focused on the development of MOF in relation 
to plasma glutamine, they did not mention the effect that specific organ failure had on plasma glutamine 
concentration.22 Thus, the plasma glutamine response to liver failure seen in adults is yet to be 
corroborated in the paediatric population. In addition, observational studies have thus far not confirmed 
Fadel et al.’s72 finding of elevated plasma glutamine among children with kidney disease. This may be 
because acute, not chronic, kidney injury occurs more frequently in a mixed PICU setting.  
 
The work done by Marino et al. provides the most comprehensive analysis of plasma glutamine in relation 
to biochemical indices in paediatric patients.21 Reasons for the differing results seen in this study could 
include cohort differences such as disease severity. At baseline, participants in this study demonstrated 
lower markers of infection and lactate, as well as more favourable markers of renal function, when 
compared with those in Marino et al.21 This could suggest that the current cohort of mixed PICU patients 
were not, on average, as ill as the group with meningococcal disease. In addition, only routine biochemistry 
was available for analysis in this study - meaning that more specialist measures were limited. It is unclear if 
the results of this study would have been different with a larger sample of all biochemical indices.   
 
Interestingly, this study demonstrated a trend toward a positive correlation with platelet count. In a series 
of biochemical papers, Vasta et al. described the active metabolism of glutamine by platelets.155 Platelets 
are known to have high energy requirements, and the role of glucose as a fuel source for these cells is well 
established.155,156 Glutamine has, however, also been identified as a source of energy for platelets - both in 
the presence or absence of glucose - and is also thought to play a role in the activation of these cells.156 
Most studies report on platelet count as a baseline measure of clinical condition rather than in relation to 
plasma glutamine concentration.13,21 In light of the active oxidation of glutamine by platelets, and based on 










Prevalence of malnutrition 
South Africa continues to face a high prevalence of childhood malnutrition. Based on the recent South 
Africa Demographic and Health Survey, an estimated 27% of children under the age of five  years are 
stunted (10% of whom are severely stunted), 3% are wasted, 6% are underweight-for-age, and 13% are 
overweight.157 This illustrates the double burden of nutrition South Africa; one of chronic under-, as well as 
over-nutrition.   
 
Considering the prevalence of malnutrition among children in South Africa, this study sought to describe 
the anthropometrical parameters of study participants, and to identify potential associations between 
nutritional status and plasma glutamine. Twenty four percent of participants were found to be stunted. 
This was marginally lower than the national estimate, and was therefore largely expected. Interestingly, 
underweight-for-age and wasting were much higher among study participants at 37% and 32% respectively 
- despite only one patient having been admitted for malnutrition alone. Overweight and obesity in this 
cohort were only identified in 3% of participants, which is half the global estimate.  
 
There is extensive literature which suggests that, worldwide, hospitalised children are at increased risk of 
malnutrition.83,158 Research suggests that 6-14% of children in hospital are malnourished, and experience 
lengthier hospital stays and increased mortality as a result.158 It makes sense that in a setting like South 
Africa where the national prevalence of malnutrition is high, sick and/or hospitalised children would be at 
even greater risk. In 2014, Brink et al. investigated the prevalence of malnutrition in 222 infants and 
children admitted to the medical paediatric ward of a tertiary hospital in South Africa. Patient age was 
comparable to the current study, ranging from one day to 14 years, comprising mainly of children below 
the age of 18 months (63%). The study found that 40.5% of participants were stunted, 33.3% were 
underweight for age, and 23.4% were wasted. Again, these findings were much higher than national 
estimates, and in the case of underweight-for-age and wasting, were more comparable to what was found 
in this study. No overweight or obese children were identified by Brink et al., which was in keeping with the 
low figures shown by this study.159  
 
Interestingly, Brink and colleagues reported that HIV-infected children, who comprised 10.8% of study 
participants, had poorer nutritional status compared to non-exposed individuals.159 In this study, 3.9% of 
participants were HIV-infected - a proportion unlikely to have been the sole cause for such high figures of 
underweight and wasting. Instead, both studies seem to reflect the growing problem of malnutrition 
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among African nations, from which similar figures of under-nutrition have been reported.160,161 These far 
exceed estimates of malnutrition during hospitalisation in developed settings.158  
Plasma glutamine and nutritional status 
Some work has been done on the effect of glutamine supplementation on nutritional status.85,162 However, 
far less attention has been paid to the interplay between nutritional status and plasma glutamine in 
patients not receiving exogenous glutamine. During critical illness it is generally accepted that glutamine 
depletion, rather than reflecting malnutrition, is likely the result of increased consumption of the nutrient 
in response to metabolic stress.26 In this context, and likely also due to the difficulties faced in measuring 
anthropometry accurately in an ICU setting, many studies on plasma glutamine in paediatric21,22 and adult59 
populations have not included nutritional status as part of their analysis.  
 
Despite this, the question remains: what is the plasma glutamine status of malnourished individuals? Based 
on the prevalence of malnutrition found in the current study, it was an important question to ask. In this 
study, significant inverse relationships were demonstrated between day 0 plasma glutamine and we ight, 
length/height, and MUAC. These relationships did not, however, account for age - meaning that the 
practical relevance of these findings is limited. When anthropometry was categorised into more meaningful 
data using Z scores, no significant differences in plasma glutamine were shown between participants who 
were underweight-for-age, stunted, or wasted compared to those who were not. Based on the results of 
this study, plasma glutamine appears unrelated to nutritional status.  
 
This result has been corroborated by most of the adult literature. In their study on adult patients with 
gastrointestinal cancer, Hulst et al. made an early link between plasma glutamine and nutritional status.  
Glutamine extraction from different intestinal sites was investigated in relation to plasma glutamine 
concentration and nutritional status. Plasma glutamine was found to be positively associated with the 
percentage ideal body weight achieved, and to glutamine extraction from the small bowel. These results 
may have been influenced by the diagnostic group studied, in which increased consumption of glutamine 
by tumours and chronic malnutrition were likely.68 This link has not however been demonstrated since. 
Instead, comparable BMI measurements have been shown among critically ill adults with low and normal 
plasma glutamine concentrations.24 In their study of adult patients with colorectal cancer, Pan et al. also 
reported no significant associations between plasma glutamine and body weight, height, or BMI. 153 
Similarly, in a cohort of patients with intestinal disease, plasma glutamine was shown to be unrelated to 
the participants’ percentage weight loss or ideal body weight.26   
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Data on nutritional status and plasma glutamine in paediatrics are extremely scarce. In their work with 
infants and children with congenital heart disease, Villares and colleagues reported that preoperative 
plasma glutamine concentrations were independent of nutritional status. This result,  among a population 
notorious for diminished nutritional status, is telling.116 It appears, therefore, that most adult and paediatric 
(albeit limited) data support the findings of this study.  
Nutritional intake 
Nutritional requirements and intake 
There has been a recent shift in the direction of nutrition support among critically ill children - with the 
focus of care being on the avoidance of both under- and over-feeding. The goal of nutrition support during 
acute illness is to provide sufficient nutrition, which supports the catabolic state and preserves lean body 
mass.163 It remains unclear as to exactly how much substrate critically ill patients require, particularly as 
both hypo- and hyper-metabolism have been identified in this extremely heterogeneous group of 
patients.130  
 
The collaborative document published by ASPEN and the Society of Critical Care Medicine (SCCM) in 2017 
provides what is currently considered the gold standard for nutritional support in the PICU setting for 
infants and children aged one month to 18 years. According to these recommendations, energy 
requirements are most accurately determined using indirect calorimetry.130 In the absence of this, energy 
requirements are admittedly an inexact science - with low-grade evidence to support specific predictive 
equations.164 This paper recommends using the Schofield equation without the addition of stress factors to 
determine energy requirements, as alternative formulae are known to either over- or under-estimate 
energy needs.130 In terms of protein requirements, an estimated 1.5 g/kg is thought to be sufficient to avoid 
a negative balance among most critically ill children.130,163 This may, however, be significantly higher in 
infants.163 Nutrient requirements for preterm infants and patients with burn injury are, however, known to 
be high. As such, these groups are excluded from the above recommendations. The nutritional 
requirements for preterm infants have been well documented.131,132 In the case of patients with burns, 
predictive equations specific to this diagnosis are encouraged. 133,134  
 
Despite conservative estimates of nutrient requirements in this study, only 5% and 6.7% of participants 
reached full energy and protein requirements respectively. In addition, median achievement of caloric and 
protein needs was low at 30.8% and 36.2%. This phenomenon of inadequate nutrient provision is not 
unique to this study, or to this particular PICU. Optimal feeding practices are made difficult in the critical -
care setting due to several factors. Haemodynamic instability, fluid restrictions, feed intolerance, and 
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obligatory periods of pre-operative fasting are some of the barriers faced.165 Mehta et al. suggest that in 
light of these difficulties, the goal of 66% of energy requirements should be met by the end of the first 
week in PICU. Energy provision within this target is thought to reduce cumulative deficits and to improve 
clinical outcome.130 Although the duration of this study did not allow for a full week’s nutrition assessment, 
16.7% of participants met this target within 48 hours of PICU admission.  
 
In both adult166 and paediatric130 critical-care settings, enteral nutrition is well established as the preferred 
mode of feeding, and should be initiated within 24-48 hours of admission. In fact, a delayed approach to 
parenteral nutrition is advised in the well-nourished critically ill child by up to one week, as a means to 
prioritise enteral feeding and to avoid PN-related complications.130 In this study, early initiation of enteral 
feeding was achieved for most (94.3%) patients, with only one patient receiving no enteral or parenteral 
nutrition in the first 48 hours of PICU stay. After 24 hours of admission, exclusive PN had been initiated in 
4.1% of participants. Because this study included preterm infants and neonates, delayed initiation of PN 
was not applicable for all patients. In short, this study found that enteral feeding was initiated early, but 
that nutrient provision was suboptimal over the first 48 hours of PICU admission – despite the conservative 
estimation of requirements.  
Plasma glutamine and nutritional intake 
In this study, it made sense to evaluate potential associations between day two plasma glutamine and the 
nutritional intake of participants in the 48 hours prior to this. No associations were identified between 
plasma glutamine and nutritional intake. Based on Mehta et al.’s target of achieving 66% of energy 
requirements, differences in plasma glutamine were investigated between those who met this energy goal 
and those who did not.130 Apart from a slight increase in plasma glutamine from admission to day two in 
those who achieved this target, no significant differences were found.   
 
Most data relating to nutritional intake and glutamine stem from intervention studies in which glutamine 
was administered as a supplement.79,80 As a result, the focus has been on the relationship between 
glutamine dosage and the subsequent plasma glutamine response. Very few studies have considered how 
energy and protein intake contribute to plasma glutamine concentration. In a small intervention among 
post-operative cardiac infants, Chaloupecky et al. investigated the effect of protein containing parenteral 
nutrition on plasma amino acid concentrations, when compared to intravenous glucose infusion. Despite 
the provision of 0.8 g/kg/day of amino acids to the intervention group on day one post-operatively, plasma 
glutamine concentrations were shown to signif icantly decline in both groups - suggesting that either 
nutritional intake is unrelated to plasma glutamine, or that the dose of protein administered was 
ineffective in maintaining plasma levels.115 Based on the recommendations of Mehta et al., it can be argued 
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that the protein dose administered to these infants was suboptimal. 130 In this study, the average protein 
intake of participants was 0.5 g/kg/day. Despite this inadequate intake, normal plasma glutamine 
concentrations were maintained from admission to day two of PICU stay. This serves to confirm that in this 
study, plasma glutamine and nutritional intake were not associated.  
 
Nutritional data from observational studies are also limited.  In their iconic studies on plasma glutamine in 
adults, neither Oudemans-van Straaten et al.24 nor Rodas et al.59 included data on nutritional intake. In 
paediatrics, Emark and colleagues described their staged approach to nutrition - from hypocaloric feeding 
on day one of PICU stay to optimal nutrition support by day five, based on the patients’ stress response.22 
Despite this background information, no nutritional data were analysed in relation to plasma glutamine. It 
would have been interesting to compare such data with the results of this study, as the approach to 
nutritional support was vastly different between cohorts.   
 
Also in paediatrics, Marino et al. reported a total provision of 0.9 g/kg/day of protein, and found that total 
glutamine intake was significantly correlated with the time taken to reach full feeds. However, neither 
protein nor glutamine intake were analysed in relation to plasma glutamine.21  This is likely because enteral 
glutamine has been reported to be an ineffective method of influencing plasma glutamine 
concentrations.21,167 Therefore, the total intake of enteral glutamine was not calculated in the current 
study. Glutamine intake would also have been difficult to assess due to the variable dietary intake of 
participants. Most paediatric feeds have an l- glutamine content of 0.3 g/100ml, whereas standard infant 
formulae contain minimal amounts, mainly in the form of glutamate.21 In this study, many older infants and 
children received a mixed hospital diet within 48 hours of PICU stay, which would have made the 
calculation of total glutamine intake challenging.  
Clinical outcome 
Markers of clinical outcome 
In this study, as in many critical-care settings, the duration of mechanical ventilation, length of PICU and 
hospital stay, and mortality were used as markers of clinical outcome. This cohort was comparable to other 
observational studies on plasma glutamine in critically ill children, in that most participants were 
mechanically ventilated. PICU and hospital LOS, at an average of six and 10 days respectivel y, were 
comparatively shorter. However, at 10.8%, mortality was noticeably higher in this patient group when 
compared to the 4.721 to 5%22 reported by other international cohorts.  
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Plasma glutamine and clinical outcome 
Surprisingly few intervention studies on plasma glutamine supplementation among critically ill patients 
have measured plasma glutamine.66,80 As a result, outcome measures are reported in relation to the 
efficacy of supplementation, rather than in relation to the plasma glutamine response.   
 
There is compelling evidence from observational studies in adult patients that both low and high plasma 
glutamine concentrations on admission to ICU are independent risk factors for mortality.24,59 There is 
limited information on what plasma glutamine concentrations during ICU stay me an, in terms of 
outcome.146   
 
Far less is known about plasma glutamine as a predictor of clinical outcome among critically i ll infants and 
children.22 The observational studies by Marino et al.21 and Ekmark et al.22 provide the most robust data on 
clinical outcome and plasma glutamine in paediatric populations.  
 
In this study, relationships were explored between clinical outcome and plasma glutamine on admission, 
day two, and the degree of change that occurred during this time. This was done to address the general gap 
in paediatric knowledge, but also to investigate if plasma glutamine during PICU stay is associated with 
clinical outcome.  
 Mechanical ventilation 
No association was found between plasma glutamine and the duration of mechanical ventilation. This is in 
contrast to an inverse relationship that was found between plasma glutamine and the length of mechanical 
ventilation in paediatric patients with meningococcal disease.21 The relationship between mechanical 
ventilation dependency and glutamine has only been consistently explored post-supplementation of the 
nutrient. While some interventions have reported reduced dependency, others have shown a significantly 
increased duration of mechanical ventilation in those receiving glutamine.77 It seems there is inconsistency 
in the reported relationship between plasma or supplemental glutamine and this outcome measure.   
 Length of Stay 
Observational studies have failed to show an association between plasma glutamine and LOS among 
critically ill adult patients who have not received exogenous glutamine.24,59 In their intervention study of 
trauma patients, Perez-Barcena et al. were the first to identify an inverse relationship between plasma 
glutamine concentration and ICU and hospital LOS.66 This relationship has also been identified in 
paediatrics. Plasma glutamine was found to be inversely correlated to PICU LOS, 21 and children with a low 
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plasma concentration of <420 umol/l tended to spend an excess of five days in the PICU.22 These results 
suggest that the lower the plasma glutamine, the longer the PICU stay. In this study, plasma glutamine and 
PICU LOS appeared unrelated. However, a positive relationship was demonstrated between plasma 
glutamine on admission and hospital LOS. Although the significance of this relationship was lost when 
statistical outliers were removed (again raising questions over the validity of excluding outliers from a 
clinical setting), a trend was still evident. This finding is unlike others in adult and paediatric literature in its 
suggestion that the higher the plasma glutamine on presentation to the PICU, the longer the hospital stay.   
 
This study also found that the less variability in plasma glutamine and glutamic acid during the first two 
days spent in PICU, the longer the hospital stay. This result has not been described before , but offers a 
glimpse into the potential importance of plasma glutamine change over time in relation to clinical outcome. 
Interestingly, the data from participants who died were excluded from LOS analyses. Most patients who 
died spent longer in PICU and in hospital compared to those who survived, and had the greatest variability 
in plasma glutamine between day 0 and day two. Therefore, the exclusion of this data may have skewed 
the above result. At face value, however, the results of this study suggest that a high plasma glutamine on 
admission, with little variation in plasma glutamine and glutamic acid concentrations ove r the first two days 
of PICU stay, place patients most at risk of increased hospital stay.  
 
Participants in this study spent less time in the PICU and/or hospital compared to other study cohorts.21,22 
Reasons for this could include between-cohort differences in diagnostic profile and disease severity (as with 
meningococcal disease compared to a mixed PICU group) or due to differences in bed availability between 
individual units. In settings such as RCWMCH where resources are limited, demand for critical-care beds is 
high - often resulting in delayed admissions and early discharges. According to Murthy and Wunsch, 
differences in patient turnover between units have the ability to skew data on clinical outcome.168 Whether 
this could have influenced the results of this study is unknown.  
 Mortality 
This study showed a tendency toward higher plasma glutamine concentration on day two among those 
who died. Elevated plasma glutamine has previously been reported in children with malaria who have died , 
when compared to those who survived.169 One would assume that this result is in keeping with the positive 
associations found in this study between plasma glutamine, mortality risk, and hospital LOS. Because 
mortality and LOS stay data were kept independent from one another it is interesting that both results 
suggest poorer clinical outcome among those with higher plasma glutamine on admission.  
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There has been a suggestion that the association between mortality and plasma glutamine may not be 
unique to glutamine itself - but may reflect general changes in amino acid concentrations in critically ill 
patients.146 In their work with septic patients, Hirose et al. found that an altered amino acid balance was 
associated with increased mortality. Maximum concentrations of glutamine, glutamate, phenylalanine, and 
histidine were shown to be significantly different between those who died compared to those  who 
survived.170 Interestingly, in this study, 57% and 50% of participants were shown to have high plasma 
glutamate and phenylalanine, respectively, on admission. This could, given more research, suggest a similar 
trend in paediatric populations as in adults. Most studies on plasma glutamine have traditionally focused 
on the amino acid independently, and/or in relation to glutamic acid. This finding may however prompt 
further studies on the interplay between different amino acids and clinical outcome.  
 
Although no significant association was found between plasma glutamine concentration and mortality, this 
study was likely underpowered to detect one - had it existed. Mortality among paediatric cohorts is lower 
than among adults, making this a difficult outcome measure to use in research. Instead, some researchers 
have used alternatives such as the PELOD score as a proxy for mortality.171 According to this score, low 
plasma glutamine on admission to PICU, as well as reduced concentrations over time, were associated with 
the development of MOF.22 This reinforces the point that a potential link between plasma glutamine status 
and mortality could, up until this point, have been overlooked by underpowered studies. In addition, Rodas 
and colleagues reported a link between plasma glutamine and six-month mortality in adults.59 The only 
study in paediatrics to have extended beyond the hospital period was Marino et al.21 Therefore, a potential 
association between plasma glutamine and mortality post-discharge has not been sufficiently investigated.  
Summary of plasma glutamine and clinical outcome 
Seen together, the results of this study, as well  as those by Marino et al.21 and Ekmark et al.,22 imply that 
paediatric patients with both low and high plasma glutamine on presentation to PICU may be more prone 
to increased morbidity and poorer outcome. This potential U-shaped curve in morbidity is how Rodas and 
colleagues described the relationship between plasma glutamine and mortality in adults.59 There are still 
many gaps in this argument, one of which is the low number of participants actually presenting with high 
plasma glutamine in this study and in others22,59 - which makes firm conclusions hard to draw. Apart from 
plasma glutamine concentration on admission to the PICU, it appears as if the degree to which plasma 
levels change over time may be significant in terms of outcome. Rigorous research will be required to 
confirm the exact relationship between plasma glutamine and clinical  outcome in critically ill infants and 
children.   
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Strengths and limitations of the study 
Strengths 
 
1. This study was exploratory, and provided a novel opportunity to investigate plasma glutamine 
concentrations among critically ill infants and children in RCWMCH. No study of this type has been 
conducted in South Africa or in Africa.  
2. Concentrations of plasma glutamine were measured on admission and on day two of PICU stay. This 
allowed for investigation into the change that occurred in plasma glutamine over the first 48 hours of 
critical illness – something which has not been reported on before in a mixed population of critically 
ill children.  
3. Both plasma glutamine as an independent measure, as well as the combined concentration of 
plasma glutamine and glutamic acid, were included in all statistical analyses. This allowed for 
comparison between studies which focused on the amino acid independently, as well as those 
reporting on both amino acids. This also ensured that any spontaneous conversion of plasma 
glutamine to glutamic acid was accounted for, thus avoiding falsely low plasma glutamine 
concentrations.  
4. In order to maintain the integrity of the blood samples collected for study purposes, a rigorous, 
standardised protocol was followed with regard to collection, storage, and analysis. Once collected, 
samples were sent (time sensitively) to the laboratory, where they were stored at -80○C, and were 
later batch analysed – thereby avoiding undue degradation of the specimens, as well as significant 
differences in storage time.  
5. Accurate anthropometry was conducted on participants by a registered dietitian as soon as was 
clinically possible, and once oedema had resolved. As a result, estimated measurements of weight 
and length or height were not used. This strengthens the study’s findings with regard to the 
nutritional status of participants. 
6. The PIM 3 scores of each participant were cross checked by a consultant paediatrician before being 
recorded for study purposes. In addition, a previous version of the same tool has been validated in 
the RCWMCH setting. Again, this strengthens the accuracy of the study’s findings with regard to 
severity of disease and mortality risk. 
Limitations 
 
1. As with all observational work, the findings of this study are merely a representation of the cohort 
that was observed and cannot be extrapolated further.  
2. Sample size was largely governed by the availability of study funds, with aminogram analysis proving 
costly. As in most research, additional study participants would have been of statistical benefit – by 
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increasing power and avoiding Type II error. In addition, the heterogeneity of diagnoses and ages of 
participants further reduced the power of the study to detect between-group differences. 
3. Consecutive sampling has the potential for bias.172 By recruiting participants over one month during 
summer time, the diagnostic profile of the study sample may have reflected seasonal differences. For 
example, from anecdotal evidence, RCWMH PICU admits more pulmonology (medical) cases over the 
winter months when compared to the summer months. 
4. Patients who were transferred to other wards before blood sampling was possible were excluded, as 
were those who did not require routine phlebotomy during their PICU stay. It can therefore be 
argued that the patients who were less ill were omitted from the study, which could potentially have 
skewed the results. 
5. Biochemistry was included in this study as a marker of clinical condition on admission. In order to 
minimise additional blood sampling for participants, only routine biochemistry was available and 
specific biochemical values could not be requested. This reduced the study’s ability to investigate the 
relationship between plasma glutamine and specific markers of infection and of renal and hepatic 
function more thoroughly. 
6. Unlike other observational studies on plasma glutamine among critically ill children, this study did 
not include a group of healthy controls. This could be considered a limitation, as comparison 
between healthy and acutely ill children in this particular setting could not be made. However, 
because most study participants demonstrated normal plasma glutamine concentrations, this 
argument could be negated.  
7. Ideally, this study would have included additional plasma glutamine measurements – both later in 
the course of PICU stay and also during convalescence. This would have allowed for comparison 
between other studies with regard to plasma glutamine response beyond the stage of acute illness. 
This would also have enabled some investigation into the possibility that the release of glutamine 
from skeletal muscle during critical illness may initially increase or maintain plasma levels – thus not 
providing an accurate representation of whole body stores. Again, the number of aminogram 
analyses was dictated by funding limitations and ethical considerations with regard to additional 
blood sampling.  
8. Because mortality is comparatively low among critically ill paediatric populations versus adults, it 
would have been useful to include an alternative outcome measure (such as the development of 
MOF), which could have served as a proxy for mortality. Because of a small sample size, significant 
associations between plasma glutamine and mortality could have been missed. As a result, this study 
allowed only for commentary on what was observed between those who died versus those who 
survived.  
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9. No outcome data were collected with regard to the development of organ failure. This prevented 
further investigation into the elevations in plasma glutamine seen in patients with renal and liver 
failure.  
Rejection or failure to reject null hypotheses 
 
Based on the results of this study, the following null hypotheses were accepted:  
 
1. Plasma amino acid concentrations do not change during the first two days of PICU stay.  
2. No relationship exists between plasma glutamine concentration and the nutritional status 
(determined by age-related Z scores) of children in PICU. 
3. No relationship exists between plasma glutamine concentration and dietary protein or energy intake 
during the first two days of PICU stay. 
4. No relationship exists between plasma glutamine and mortality.  
 
The remaining null hypotheses were rejected: 
 
5. No relationship exists between plasma glutamine concentration and clinical condition on admission 
to PICU. 
6. No relationship exists between plasma glutamine concentration and PICU or hospital LOS. 




The aim of this cross-sectional study was to describe plasma glutamine concentrations of critically ill infants 
and children on admission to and during the first two days of PICU stay. Furthermore, the study sought to 
identify associations between plasma glutamine and markers of clinical condition on admission (diagnosis, 
presence or absence of infectious disease, severity of disease, and biochemistry profile), nutritional status,  
dietary intake, and indicators of clinical outcome (duration of mechanical ventilation, PICU and hospital 
LOS, and mortality). Plasma glutamine was expressed both as an independent measure, and as the 
combination of plasma glutamine and glutamic acid, to account for the conversion of glutamine to 
glutamate during processing.  
 
For most participants, plasma glutamine concentration fell within normal limits on both admission (median 
556.5 umol/l, IQR 459-664.5 umol/l) and on day two of PICU stay (median 529.0 umol/l, IQR 356.0-716.0 
umol/l). Relatively few (n = 13, 17.1%) participants presented with low plasma glutamine on admission, and 
even fewer demonstrated elevated concentrations (n = 4, 5.3%). No significant changes in plasma 
glutamine occurred over the first 48 hours of PICU stay. This suggests that participants who were glutamine 
deplete on admission were more likely to have low concentrations 48 hours into their PICU stay. Based on 
these results, the null hypothesis regarding plasma glutamine concentration was accepted. The findings of 
this study were unexpected, as previous observational research found glutamine depletion among greater 
proportions of children on admission to PICU. In addition, previous studies showed some improvement in 
plasma glutamine over time.  
 
Plasma glutamine on presentation to the PICU was investigated in relation to the diagnostic profile of 
participants. The cohort was largely made up of elective surgical patients (n = 41, 53.9%), and was heavily 
weighted by cardiology as a primary diagnosis (n = 37, 47%). Some of the most significant findings of this 
study were the differences shown in plasma glutamine concentrations between diagnostic categories: 
medical and elective surgical (p = 0.007) and medical and trauma diagnoses (p = 0.013), in particular. On 
presentation to the PICU, participants admitted for trauma demonstrated the lowest plasma glutamine 
(mean 450.3 ± 166.7 umol/l), and medical diagnoses the highest (800.1 ± 317.6 umol/l). Low plasma 
glutamine was demonstrated in 50% (n = 3) of trauma admissions – highlighting this subgroup as the most 
vulnerable to glutamine depletion. Again, these findings are not corroborated by existing literature on 
adults, which demonstrates medical patients to be the most susceptible to glutamine depletion on 
presentation to the ICU.  
 
Differences in plasma glutamine and glutamic acid were also evident between the primary diagnoses 
cardiology and gastroenterology (p = 0.018), and between sepsis and pulmonology (p = 0.031), burns (p = 
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0.035), gastroenterology (p = 0.006), and ‘other’ (p = 0.049). Participants admitted for sepsis were observed 
to have the highest plasma glutamine (736.3 ± 142.5 umol/l), whereas gastroenterology diagnoses had the 
lowest (432.4 ± 149.2 umol/l). These findings deviate from existing observational research, which 
demonstrates low plasma glutamine among septic adult patients. Although less is known in paediatrics, 
there has been a similar suggestion of glutamine depletion among septic patients. In this study, p ost-
operative cardiology cases, which comprised nearly half the participants, had normal plasma glutamine 
concentrations on day 0 and day two. Again, this is a novel finding, as existing literature documents lo w 
plasma glutamine in the post-operative period. Based on the finding that plasma glutamine concentration 
differs according to diagnostic profile, the null hypothesis with respect to clinical condition on admission 
was rejected. 
 
Based on severity of disease scoring, this study reported a median risk of participant mortality of 1.4% (IQR 
0.8-3.9%). Plasma glutamine tended to be lower among those with reduced risk of mortality (Spearman r = 
0.22, p = 0.052). Similarly, a positive association was found between a combined value of plasma glutamine 
and glutamic acid and mortality risk (Spearman r = 0.23, p = 0.046). Both correlations were, however, weak 
and significance was lost with the removal of outliers. Although these findings provide a mere suggestion of 
an association between mortality risk and plasma glutamine – no such relationship has been identified in 
adult or paediatric literature. 
 
No further associations were demonstrated between plasma glutamine and other markers of clinical 
condition. In terms of infectious disease, most participants were HIV (n = 72, 94.7%) and TB (n = 71, 93.4%) 
negative - although at 3.9% (n= 3) the prevalence of HIV was double the national estimate. Plasma 
glutamine on admission was comparable between those who were infected and those who were not. This 
was the first study to investigate the relationship between plasma glutamine concentration and infectious 
disease in critically ill children.  
 
This study relied on routine biochemistry as a measure of clinical condition on admission. No associations 
were demonstrated between plasma glutamine and any biochemical indices – including markers of 
infection, albumin, lactate, and measures of renal and hepatic functioning. However, participants with 
lower platelet counts tended to have lower plasma glutamine on admission (Spearman r = 0.22, p = 0.058). 
Although the link between glutamine as a fuel source for platelets has been established, no association 
between plasma glutamine and platelets among critically ill patients has been reported to date. Glutamine 
depletion has previously been associated with low albumin, and with elevated lactate, Il-6, and CRP.  
 
Under-nutrition of participants in this study exceeded national estimates, with 37% (n = 23) of children 
presenting underweight-for-age, 24.2% (n = 15) stunted, and 32.2% (n = 20) wasted. Over-nutrition was 
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significantly lower at 3.2% (n = 2). No association was found between plasma glutamine and nutritional 
status – a finding that has been supported by existing research in adults and children. Instead, plasma 
glutamine depletion during critical illness is thought to be the result of increased demand for the nutrient 
during metabolic stress. In light of these results, the null hypothesis regarding nutritional status and plasma 
glutamine was accepted.  
 
Although early enteral feeding was established for most (n = 68, 94.3%) participants in this study, energy 
and protein requirements were met by only 5% (n = 3) and 6.7% (n = 4) respectively in the first 48 hours of 
PICU stay. Inadequate nutritional intake is well documented in PICU settings and was not unique to this 
study. No relationship between plasma glutamine and nutritional intake was observed. As a result, the 
relevant null hypothesis was accepted. Limited research exists on nutritional intake and plasma glutamine 
concentration, with most data stemming from interventions that administered glutamine as a supplement. 
In children, plasma glutamine has been shown to reduce significantly despite the administration of 0.8 
g/kg/day of protein. In contrast, with a lower protein intake of 0.5 g/kg/day in this study, plasma glutamine 
remained on average, normal – thereby confirming that plasma glutamine status and nutritional intake 
appear to be unrelated.  
 
Participants in this study spent on average 6 (±10) and 10 days (IQR 7-20 days) in the PICU and in hospital 
respectively, and most (n = 56, 74.7%) required ventilatory support. Eight children (10.5%) died during the 
course of this study. No associations were demonstrated between plasma glutamine and the duration of 
mechanical ventilation or PICU LOS. A positive association was identified between plasma glutamine on 
admission and hospital LOS (Spearman r = 0.26, p = 0.032), although only a trend existed when statistical 
outliers were removed (Spearman r = 0.23, p = 0.067). These findings differ f rom existing research in 
children, which has shown a link between glutamine depletion and PICU, not hospital, LOS. An interesting 
and inexplicable finding of this study was the inverse relationship between the change that occurred in 
plasma glutamine and glutamic acid and hospital LOS (Spearman r = -0.34, p = 0.046). This has not been 
described elsewhere but suggests that the change which occurs in plasma concentrations over time may 
have some significance in terms of outcome. Based on these results, the null hypothesis regarding PICU and 
hospital LOS was rejected. 
 
Although no association was found between plasma glutamine and mortality, this study was likely 
underpowered to detect one – had it existed. Adult studies have established an association between 
plasma glutamine on admission to ICU and mortality. Conclusions regarding mortality are more difficult to 
achieve in paediatric cohorts, as mortality rates tend to be lower and research studies smaller. A notable 
observation in this study, however, was that participants who died tended to have higher plasma glutamine 
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on day two of PICU stay (p = 0.057). Despite this, the null hypothesis relating to plasma glutamine and 
mortality was accepted. 
 
This study was strengthened by rigorous laboratory protocols, measurement of plasma glutamine both 
independently and in combination with glutamic acid, and through accurate anthropometry and severity of 
disease scoring. The exploratory nature of the study also meant that it could expand on the limited 
knowledge base within this field. It was weakened, however, by the small, heterogeneous sample size, 
consecutive sampling method, limited number of plasma glutamine measures per participant, the reliance 
on routine biochemistry, and on the absence of a healthy control group. In addition, as with all 
observational work, the findings of this study cannot be extrapolated further.  
 
In summary, this study demonstrates normal plasma glutamine among the majority of infants and children 
admitted to the RCWMCH PICU over a one-month period, with no significant concentration changes 
occurring over the first 48 hours of PICU stay. The findings of this study do not, therefore, support routine 
supplementation among critically ill  children. The difference in plasma glutamine concentration shown 
between diagnostic groups is an important finding, with trauma and sepsis diagnoses emerging most 
susceptible to lower and higher concentrations respectively. This study also provides some suggestion that 
high plasma glutamine concentrations during the acute phase of critical illness may be associated with 
increased mortality risk and poorer outcome. When combined with existing data in paediatrics, this could 
suggest that – as in adult populations – both low and high plasma glutamine concentrations are associated 
with adverse effect. Extensive research is, however, needed to provide clarity on the relationship between 
plasma glutamine and clinical outcome. 
 
In their review article, Smedberg and Werneman asked the question – “Is the glutamine story over?”146 In 
paediatrics, with such limited data available, and in light of the findings of this study, it appears as if the 
story has barely begun.  
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7. Recommendations  
1. Clinical recommendation 
This study found that plasma glutamine concentrations were normal on admission and on day two of 
PICU stay. This result does not support routine supplementation of glutamine to critically ill children.  
 
2. Research recommendations 
Most data on glutamine in paediatric populations stem from intervention studies, with surprisingly few 
having measured plasma concentration prior to supplementation. The safety of blanket 
supplementation of glutamine has, however, recently been questioned in adult literature. As a result, 
there is a need for increased understanding of plasma glutamine concentrations in specific populations. 
There is a paucity of data from observational studies on plasma glutamine concentration, particularly 
among critically ill children. As such, more observational research in this group is required before 
further interventions can take place.  
 
2.1 Based on the findings of this study, the following areas require further research in relation to 
plasma glutamine: 
 
2.1.1. Diagnostic profile 
Observational studies on plasma glutamine in critically ill children have, to date, included 
participants with different diagnostic profiles – making comparison difficult. Studies conducted in 
mixed PICU settings (such as this one) include heterogeneous patient populations, making it 
challenging to identify between-group differences. Research into specific diagnostic groups will 
allow for firmer conclusions to be drawn. The findings of this study would suggest that trauma and 
sepsis diagnoses warrant further study to confirm whether these groups are susceptible to more 
extreme plasma concentrations, and if the glutamine status of children within these diagnostic 
groups is consistently different to adult populations. 
 
2.1.2. Severity of disease and mortality risk 
Only one previous observational study in paediatrics included severity of disease scoring – using a 
different tool to the PIM 3 applied in this study. Because scoring systems are not directly 
equivalent, the standardised use of a scoring system across studies would allow for meaningful 
comparison. This study suggested a potential association between plasma glutamine and mortality 
risk. Because so few have investigated this relationship, more attention is certainly warranted.  
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2.1.3. Markers of renal and hepatic functioning 
Evidence from adult populations suggests that plasma glutamine is elevated during liver and 
chronic renal failure, however limited evidence for this exists in children. This study found no 
association between plasma glutamine and biochemical markers of renal and hepatic functioning – 
but was limited by the fact that many patients did not have these indices measured during their 
stay. A combination of biochemical testing and the diagnosis of renal or hepatic failure would be 
useful to include in future studies on plasma glutamine in children. 
 
2.1.4. Markers of infection 
The relationship between plasma glutamine and biochemical markers of infection needs further 
study, with only one observational study in children having demonstrated an inverse relationship 
between CRP and plasma glutamine. This study observed inverse but non-significant associations 
between markers of infection and plasma glutamine – but again, data were limited.  
 
2.1.5. Clinical outcome 
Because death rates are lower among children compared to adults, mortality is a difficult outcome 
measure to use in paediatric research. In fact, many studies, including this one, are underpowered 
to detect significant changes in mortality. Large, sufficiently powered observational studies are 
required to establish if, as in adults, a link between plasma glutamine and mortality exists. Failing 
this, more attention needs to be given to outcome measures such as the PELOD score, which could 
be used as a proxy for mortality.  
 
Observational studies in children have, to date, only established an inverse relationship between 
plasma glutamine and PICU LOS. This study suggested that higher plasma glutamine resulted in a 
longer hospital stay. Both these relationships require further study.  
 
2.2 With regard to plasma glutamine concentration, the results of this study suggest that more 
attention be given to: 
 
2.2.1 Both low and high plasma glutamine concentrations 
Unlike other research, this study did not identify plasma glutamine depletion as a significant 
problem among critically ill children. It did, however, suggest that higher plasma glutamine may be 
associated with mortality risk, hospital LOS, and could be more prevalent in those who die. A link 
between mortality and low and high plasma glutamine has been established in adults, and the 
association between glutamine depletion and morbidity has been identified in children. This, in 
addition to what has been demonstrated in this study, suggests that attention needs to be paid to 
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both low and high plasma glutamine concentration – particularly with regard to mortality risk 
scoring and clinical outcome. This will provide more definitive answers regarding the need for, and 
safety of, glutamine supplementation in paediatric populations.  
 
2.2.2 Changes in plasma glutamine over time 
The clinical significance of the direction and degree of plasma glutamine change over time should 
also be explored in more detail. There is a discrepancy in the existing literature over the direction 
of plasma glutamine change over time. In certain adult populations, plasma glutamine has been 
shown to remain low for some time, whereas gradual improvement has been demonstrated in 
children. Direct comparison is, however, made difficult by the different time -frames used by each 
study. This study found an association between plasma glutamine (in combination with glutamic 
acid) change and hospital LOS – suggesting that the degree of change may be clinically relevant. In 
short, more information is required regarding how plasma glutamine changes over time, and if this 
is clinically important. 
 
2.2.3 Measurement of plasma glutamine 
Because glutamine spontaneously converts to glutamate, there remains uncertainty about whether 
to measure plasma glutamine independently or in combination with glutamic acid. Existing 
observational and intervention studies have employed different approaches. While a combined 
measure of plasma glutamine and glutamic acid may avoid falsely low concentrations, there are, as 
yet, no defined reference ranges for the sum of these two amino acids. This study used both 
methods to measure plasma glutamine and found different results between the two. It is therefore 
extremely important that consensus is achieved over how best to measure plasma glutamine, and 
that studies employ a standardised approach going forward. Only then can meaningful evaluation 
of the literature begin. 
 
2.2.4 Reference ranges for plasma glutamine 
Similarly, there is no unanimity over the reference ranges for plasma glutamine in children. Age -
specific reference ranges exist, but are not reported on in the paediatric literature. Instead, some 
have utilised cut offs established in adult studies based on clinical outcome – cut offs that have 
been confirmed by only one paediatric study. As a result, plasma glutamine concentrations are 
categorised differently across the literature, making conclusions hard to draw. Consensus is again 
required, and a uniform approach is needed.  
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 You can withdraw from the study at any time without giving a reason
 Your child’s medical care will not change in any way if you take part or do not take part in
the study
What is the research about? 
This research is about glutamine, which is a type of amino acid. Amino acids are the smallest 
building blocks of protein in the body. When people are very ill or injured, their bodies use more 
glutamine for healing. This means that their body’s stores of glutamine may be low.  Until now, 
most research has been done in adult patients and very little has been done in children. It is 
important for us to understand if children’s glutamine stores are low when they are ill.   
This research will investigate the blood levels of glutamine in children who are very ill. We will also 
investigate differences in levels according to the type of illnesses children have and how ill they 
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Addenda A: Participant information leaflet and consent form 
TITLE OF THE RESEARCH PROJECT: 
Plasma glutamine concentration among critically ill children 
REFERENCE NUMBER: S16/05/085 (Stellenbosch University) 681/2016 (UCT) 
PRINCIPAL RESEARCHER: Mrs Joanna Eksteen (Wilson) 
ADDRESS:   
Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch University 
CONTACT NUMBER: 
Your child is being invited to take part in a research study. It is very important that you understand 
what the study is about before you agree to participate. The study will be explained to you in 
person and written information will be given to you to keep. Please tell the researcher if you do 
not understand any part of what is being explained.  
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and the University of Cape Town and  will be conducted according to the ethical 
guidelines and principles of the international Declaration of Helsinki, South African Guidelines for 
Good Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for Research. 
Do you have to participate in the study? 
You do not have to take part if you do not wish to. Participation in the study is voluntary. It is also 
very important for you to know the following: 
112 
are. We also want to see if glutamine levels affect children’s outcome, for example, how long they 
stay in hospital. This will help us to better understand glutamine levels in sick children.   
Why has your child been invited to participate? 
This study aims to gather information about plasma glutamine from all patients admitted to the 
Paediatric Intensive Care Unit during the month of August 2016. Your child has been invited to 
participate in this study because he or she has been admitted during this time.  
What will be expected of you and your child? 
Two additional blood samples will be taken from your child: one on admission to the Intensive 
Care Unit and another on day 2 of their stay.  Please note that: 
 This will be taken at the same time as other routine blood tests
 Blood will be collected safely by a health care professional
During their stay in hospital your child will be weighed and measured. This will take about 10 
minutes and will involve: 
 Standing on or being placed on a scale
 Standing or lying down for a height measurement
 Having a tape measure placed around the arm





 Blood test results
What are the risks and benefits involved in taking part? 
 The study has been approved by the Health Research Ethics Committee. This means that
the researchers have to adhere to certain strict standards to ensure that the study is safe
and ethical.
 Blood will be drawn in a safe and clean way by a health care professional to reduce the risk
to your child. This will not require a new needle to be placed, so your child will not feel
pain.
 If your child becomes distressed during weighing or measuring, we will stop and try again
later. If the researcher identifies your child to be malnourished, he/ she will be referred to
a dietitian.
 By participating in the study, you and your child will not benefit directly. We hope that
what we learn from the study will help us to better understand how to care for sick
children in the future.
How will your child’s information be used? 
 Only one member of the research team will have access to your child’s medical file
 Any information recorded will be labelled using a special code
 In this way your child’s name will not be used
Stellenbosch University  https://scholar.sun.ac.za
113 
 All information will be stored by the research team for 5 years before being destroyed
 Information will be entered into a computer database which will only be viewed by three
members of the research team
 However, sponsors of the study, study monitors, auditors or Human Research Ethics
Committee members may in some circumstances need to inspect research records
 If the results of this study are shared, no names will be used
 Blood samples will be stored in the hospital’s laboratory until they are analysed. They are
then stored for a further 2 months until they are destroyed.
Will you be paid to take part in this study and are there any costs involved? 
You will not be paid to participate in the study, and there will be no costs involved if you do take 
part.  
Who can you contact for more information? 
If you have any questions or concerns, please contact: 
 Joanna Eksteen
o Telephone: 
 Should you have concerns or complaints which cannot be addressed by the 
principle investigator you are welcome to contact:
 The Health Research Ethics Committee (University of Stellenbosch)
o Telephone: 
 The University of Cape Town Health Research Ethics Committee Chair
o Professor Marc Blockman
o Telephone: 
Declaration by parent/ legal guardian 
I…………………………………..………………parent/legal guardian of 
……………………………………………………(Child name and surname) 
agree that my child can take part in the research study ‘Plasma glutamine concentration among 
critically ill children’. 
I declare that: 
 I have read and understood the consent form (or had it explained to me)
 The consent form is written in a language which I understand
 I have had a chance to ask questions and all my questions have been answered
 I have not been pressurised to take part in this study
 I understand that participation in this study is voluntary
 I understand that I may choose to leave the study at any time
Signed at (place) ......................…........…………….. on (date) …………....………...2016 
 ......................................................................  ................................................................... 
Signature of parent/ legal guardian Signature of witness 
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Declaration by investigator 
I (Name of researcher) ……………………………………………..……… declare that: 
 I have explained the information in this document to:
……………………………………………………(Parent/ legal guardian) 
 I encouraged him/her to ask questions and took time to answer each one
 I am satisfied that he/she understands all aspects of the research
Signed at (place) ......................…........…………..on(date)…………....………………2016 
 ......................................................................  ................................................................... 
Signature of investigator Signature of witness 
Declaration by interpreter 
I (name) ……………………………………………..……… declare that: 
 I assisted the investigator (name) ………………………………………. to explain the information 
in this document to (name of participant) ……………..…………………………….. using the 
language medium of Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer them.
 I conveyed a factually correct version of what was related to me.
 I am satisfied that the participant fully understands the content of this informed
consent document and has had all his/her question satisfactorily answered.
Signed at (place) ......................…........…………….. on (date) ……………….2016. 
 ......................................................................  ................................................................... 
Signature of interpreter Signature of witness 
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Addenda B: Participant information leaflet and assent form 
RESEARCH PROJECT TITLE: Blood levels of glutamine in very sick children 
REFERENCE NUMBER: S16/05/085 (Stellenbosch University) 681/2016 (UCT) 
RESEARCHER: Mrs Joanna Eksteen (Wilson) 
ADDRESS:   
Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch University 
CONTACT NUMBER: 
What is RESEARCH? 
Research is something we do to find new knowledge about the way things (and people) work.  We 
use research projects or studies to help us find out more about disease or illness. Research also 
helps us to find better ways of helping or treating children who are sick. 
What is this research project all about? 
This research is about glutamine which is a type of protein. When people are sick their bodies use 
more glutamine for healing. This can mean that the body’s stores of glutamine are low. This 
research project aims to measure the amount of glutamine there is in the blood of children who 
are very sick. This will help us to understand how to treat children who are sick. 
Why have I been invited to take part in this research project? 
 All children who are in the intensive care unit during the month of November are being asked to 
take part in this research. You have been invited to take part because you are in the intensive care 
unit during this time.  
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Who is doing the research? 
The main researcher is Joanna Eksteen (Wilson). She is a dietitian who works for Red Cross 
Children’s Hospital. She is also a student at the University of Stellenbosch. She will be asking you if 
you want to take part and will be collecting most of the information for the study. 
What will happen to me in this study? 
During the first few days in the intensive care unit the doctors will take some blood from you 
every day. This helps them to decide how to treat your illness. For this study we will take a little bit 
of extra blood from you on the day you are brought in and again on your second day in the 
intensive care unit. You will not have to be pricked again for this, as the doctors will do this all at 
the same time. This is done in a safe and clean way. 
The researcher will measure your weight, and height. When you are well enough and are not in 
any pain, you will be asked to stand on a scale to be weighed and for your height to be measured. 
The researcher will also look at your medical information and will record information about why 
you were brought into the hospital, what happened to you in hospital, and how long you stayed in 
the hospital. 
Can anything bad happen to me? 
This study is designed not to harm you or place you at any risk. The blood tests and measurements 
will not cause you pain and will be done in a safe and clean way. If you feel upset at any time 
please let your parents and the researcher know. 
Can anything good happen to me? 
You will not be given anything for taking part in this research. You will be treated the same as all 
the other patients.  
Will anyone know I am in the study? 
The researcher will give every child who takes part in the study a special number. This number will 
be used instead of your name. In this way only the researcher will know that the information 
collected is yours. Your number and information will be stored on the computer and will be seen 
by only 3 people on the research team. If we write about what we found in this study, we will not 
use your name. 
Who can I talk to about the study? 
If you have any questions about the research or if you are worried 
about anything you can telephone: 
 Joanna Eksteen (Main Researcher)
o Telephone: 
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If your questions have not been properly answered you can also contact: 
 The Health Research Ethics Committee (University of
 Stellenbosch) 
o Telephone: 
 The University of Cape Town Health Research Ethics Committee Chair
o Professor Marc Blockman
o Telephone: 
What if I do not want to do this? 
You do not have to take part in this research if you do not want to. You can say no at any time, 
even if your parents have agreed for you to take part. Nothing bad will happen to you and you will 
not be in trouble. 
Do you understand this research study and are you willing to take part in it? 
YES NO 
Has the researcher answered all your questions? 
YES NO 
Do you understand that you can pull out of the study at any time? 
YES NO 
_________________________ ____________________ 
Signature of Child  Date 
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Addenda C: Data Collection Sheet 
DATA COLLECTION SHEET 
Participant number 




2. Date of birth of patient
Day Month Year 
ADMISSION INFORMATION 
3. Date of admission data collection 
4. Date of hospital admission 
5. Date of PICU admission  
6. Admitted from    (X) Home   Ward 
MEDICAL INFORMATION 
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9. Infectious Disease  (X) 
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10. Risk of mortality: PIM 3 Score
BIOCHEMISTRY 















 (mmol/l) Highest:  
DATA TO COLLECT AT PICU ADMISSION AND DAY 2
12.1 Plasma glutamine on admission 
NOTE: If Hb is known to be <7 g/dl on admission the patient must be excluded from the study 
Date of sample Time of sample Value 
12.2 Plasma glutamine  at 48 hours 
NOTE: if Hb is <7 g/dl do not take the second blood sample 
Date of sample Time of sample Value 
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DATA TO COLLECT ON DAY 2 OF PICU STAY
FEED INFORMATION 







Total volume prescribed 
Total volume achieved 
13.3Oral 
Feed type 
Total volume prescribed 
Total volume achieved  
DATA TO COLLECT AT PICU DISCHARGE
ANTHROPOMETRY 




Measurement not possible 
14.2 Length/ height 
Recumbent length 
Standing height 
Measurement not  possible 
15. Measurements
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15.1 Weight (kg) 
15.2 Length/ height (cm) 
15.3 MUAC (cm) 
16.1 Presence of ascites    (X) Yes No 
16.2 Presence of oedema 
Location of oedema Category Indicate Option (X) 
No visible oedema None 
Both feet/ankles Mild (+) 
Both feet plus lower legs, hands/ 
lower arms Moderate (++) 
Generalised oedema Severe (+++) 
PICU DISCHARGE INFORMATION 
17. Date of PICU discharge data collection 
18. Date of PICU discharge 
19. Discharge Options   (X) 
19.1 Transferred to another hospital 
19.2 Transferred to another ward 
i. Ward and date
19.3  Deceased in PICU 
i. Date
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MEASURES OF CLINICAL OUTCOME 
20. Ventilation Requirements
20.1 Length of time on mechanical ventilation (days)  
DATA TO COLLECT AT HOSPITAL DISCHARGE
21. Date of hospital discharge
22. If deceased, date
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